21679-14-1 | 9-b-D-Arabinofuranosyl-2-fluoroadenine

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
1g	99%(HPLC)	in stock	$40.00	$28.00
5g	99%(HPLC)	in stock	$177.00	$124.00
25g	98%	in stock	$417.00	$292.00

Description

• Catalog Number: AB52362
• Chemical Name: 9-b-D-Arabinofuranosyl-2-fluoroadenine
• CAS Number: 21679-14-1
• Molecular Formula: C10H12FN5O4
• Molecular Weight: 285.2318
• MDL Number: MFCD00132942
• SMILES: OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1nc(F)nc2N

Computed Properties

• Complexity: 367
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 20
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 2
• XLogP3: -0.6

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

  Leukemia 20150101

• Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.

  PloS one 20140101

• ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

  Biochemical pharmacology 20130401

• A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia.

  Cancer treatment reviews 20121201

• Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.

  Medical oncology (Northwood, London, England) 20121201

• Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20121101

• Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.

  Leukemia & lymphoma 20121101

• [Detection and impact of minimal residual disease on outcome of chronic lymphocytic leukemia].

  Orvosi hetilap 20121014

• The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.

  Investigational new drugs 20121001

• Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.

  Bone marrow transplantation 20121001

• Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity.

  Bone marrow transplantation 20121001

• Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.

  Leukemia & lymphoma 20121001

• N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.

  Leukemia 20121001

• Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.

  Journal of proteome research 20120907

• Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

  Medical oncology (Northwood, London, England) 20120901

• Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.

  Medical oncology (Northwood, London, England) 20120901

• Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.

  Bone marrow transplantation 20120901

• Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival.

  Bone marrow transplantation 20120901

• A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.

  Bone marrow transplantation 20120901

• Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.

  Leukemia & lymphoma 20120901

• Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120901

• Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.

  Haematologica 20120901

• A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome.

  Annals of hematology 20120901

• Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.

  American journal of hematology 20120901

• Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis.

  Leukemia research 20120901

• Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.

  Pediatric hematology and oncology 20120901

• Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation.

  Cancer 20120815

• ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

  Blood 20120809

• Treatment of older patients with mantle-cell lymphoma.

  The New England journal of medicine 20120809

• Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant.

  Leukemia & lymphoma 20120801

• Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.

  Clinical lymphoma, myeloma & leukemia 20120801

• Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120801

• Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

  Cell death & disease 20120801

• Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.

  Blood 20120712

• Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120710

• [Modern times: back to past, back to future].

  Medicina clinica 20120707

• The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.

  Leukemia & lymphoma 20120701

• Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.

  Leukemia & lymphoma 20120701

• Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120701

• Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.

  Annals of hematology 20120701

• Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study.

  Journal of cancer research and clinical oncology 20120701

• Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.

  Biochemical pharmacology 20120701

• Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120701

• miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes.

  Carcinogenesis 20120701

• Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.

  Die Pharmazie 20120701

• T-cell large granular lymphocytic leukemia: treatment experience with fludarabine.

  Clinics (Sao Paulo, Brazil) 20120701

• Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.

  Gene 20120615

• A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.

  Investigational new drugs 20120601

• Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120601

• Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.

  Haematologica 20120601

• Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells.

  Haematologica 20120601

• Matched sibling donor stem cell transplantation for Fanconi anemia patients with T-cell somatic mosaicism.

  Pediatric transplantation 20120601

• T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

  British journal of haematology 20120601

• Reduced-intensity conditioning in unrelated donor cord blood transplantation for familial hemophagocytic lymphohistiocytosis.

  American journal of hematology 20120601

• Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.

  Proteomics. Clinical applications 20120601

• Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

  Blood 20120531

• Risk categories and refractory CLL in the era of chemoimmunotherapy.

  Blood 20120503

• Oral cryotherapy can significantly reduce oral mucositis but not acute GVHD incidence in Flu/Mel conditioning allo-SCT.

  Bone marrow transplantation 20120501

• Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation.

  Bone marrow transplantation 20120501

• Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.

  Annals of hematology 20120501

• Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.

  Leukemia & lymphoma 20120501

• The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.

  Leukemia & lymphoma 20120501

• Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells.

  Leukemia & lymphoma 20120501

• Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia.

  Leukemia 20120501

• Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.

  Naunyn-Schmiedeberg's archives of pharmacology 20120501

• Nonmyeloablative conditioning regimen to increase engraftment of gene-modified hematopoietic stem cells in young rhesus monkeys.

  Molecular therapy : the journal of the American Society of Gene Therapy 20120501

• The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT.

  Bone marrow transplantation 20120501

• Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.

  Blood reviews 20120501

• The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

  Oncotarget 20120501

• Fludarabine may overcome resistance to rituximab in IgM-related neuropathy.

  Journal of the neurological sciences 20120415

• Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.

  Bone marrow transplantation 20120401

• The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120401

• LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.

  Leukemia research 20120401

• Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.

  Journal of immunology (Baltimore, Md. : 1950) 20120401

• FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients.

  Journal of pediatric hematology/oncology 20120401

• Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia.

  Blood 20120329

• Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.

  Blood 20120322

• Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120320

• Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120310

• Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.

  Bone marrow transplantation 20120301

• FAME, a novel conditioning regimen for allogeneic stem cell transplantation for lymphoma, does not earn fame.

  Hematological oncology 20120301

• The effect of zinc sulfate in the prevention of high-dose chemotherapy-induced mucositis: a double-blind, randomized, placebo-controlled study.

  Hematological oncology 20120301

• Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells.

  The British journal of nutrition 20120301

• Successful cord blood transplantation with reduced-intensity conditioning for childhood cerebral X-linked adrenoleukodystrophy at advanced and early stages.

  Pediatric transplantation 20120301

• Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?

  Leukemia & lymphoma 20120301

• Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.

  Leukemia & lymphoma 20120301

• Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20120301

• Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20120301

• Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120301

• Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.

  Haematologica 20120301

• Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.

  Blood 20120301

• Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia.

  American journal of hematology 20120301

• Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

  Annals of oncology : official journal of the European Society for Medical Oncology 20120301

• Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.

  Nature cell biology 20120301

• Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

  The Korean journal of internal medicine 20120301

• [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20120301

• Alemtuzumab for patients with chronic lymphocytic leukaemia.

  The Cochrane database of systematic reviews 20120215

• Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.

  Bone marrow transplantation 20120201

• Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.

  Bone marrow transplantation 20120201

• A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120201

• Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.

  Annals of hematology 20120201

• Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201

• Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.

  Cancer chemotherapy and pharmacology 20120201

• Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia.

  Leukemia & lymphoma 20120201

• Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.

  Leukemia & lymphoma 20120201

• Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44.

  Journal of clinical immunology 20120201

• CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.

  Haematologica 20120201

• Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.

  Clinical lymphoma, myeloma & leukemia 20120201

• Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20120201

• Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20120201

• Individualized fludarabine-based regimen in elderly patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

  Advances in therapy 20120201

• Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart.

  The Journal of biological chemistry 20120120

• Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.

  Cancer 20120115

• Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

• Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120115

• Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas.

  Bone marrow transplantation 20120101

• Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.

  Bone marrow transplantation 20120101

• Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.

  Leukemia & lymphoma 20120101

• Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials.

  Leukemia & lymphoma 20120101

• Progressive multifocal leukoencephalopathy after treatment with rituximab, fludarabine and cyclophosphamide in a patient with chronic lymphocytic leukemia.

  Leukemia & lymphoma 20120101

• FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.

  American journal of hematology 20120101

• Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.

  European journal of haematology 20120101

• Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with E. coli purine nucleoside phosphorylase: palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides.

  European journal of medicinal chemistry 20120101

• Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning?

  Clinical transplantation 20120101

• The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes.

  PloS one 20120101

• Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.

  Pharmacological reports : PR 20120101

• Epstein-Barr virus-negative classical Hodgkin's lymphoma in a patient with T-cell prolymphocytic leukemia treated with fludarabine.

  Journal of clinical and experimental hematopathology : JCEH 20120101

• Cytomegalovirus oesophagitis following treatment with fludarabine for refractory lymphoplasmacytic lymphoma.

  BMJ case reports 20120101

• Successful treatment of γ-heavy-chain disease with rituximab and fludarabine.

  Acta haematologica 20120101

• Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.

  Blood 20111222

• Chemotherapy: New FluCam combination therapy has familiar limitations.

  Nature reviews. Clinical oncology 20111206

• Successful reduced-intensity SCT from unrelated cord blood in three patients with X-linked SCID.

  Bone marrow transplantation 20111201

• Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.

  Bone marrow transplantation 20111201

• Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.

  Hematological oncology 20111201

• Waldenström's macroglobulinemia and nephrotic syndrome with membranous nephropathy.

  Scandinavian journal of urology and nephrology 20111201

• Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

  Clinical lymphoma, myeloma & leukemia 20111201

• IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms.

  The Journal of investigative dermatology 20111201

• Gastric mucosa-associated lymphoid tissue lymphoma: how to attack the T… for two?

  Leukemia & lymphoma 20111201

• A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma.

  Clinical lymphoma, myeloma & leukemia 20111201

• Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with fludarabine: effect on tumor microenvironment.

  Leukemia & lymphoma 20111201

• The effects of chemotherapeutic agents on differentiated chordoma cells.

  Journal of neurosurgery. Spine 20111201

• Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.

  The Lancet. Oncology 20111201

• Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome.

  The American Journal of dermatopathology 20111201

• Fludarabine nucleoside modulates nuclear 'survival and death' proteins in resistant chronic lymphocytic leukemia cells.

  Nucleosides, nucleotides & nucleic acids 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient.

  Experimental oncology 20111201

• Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20111201

• Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.

  Cancer 20111115

• Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

  Blood 20111110

• Anti-CD20: tales of identical twins?

  Blood 20111110

• Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

  JAMA 20111102

• Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.

  JAMA 20111102

• Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.

  International journal of radiation oncology, biology, physics 20111101

• Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes.

  Bone marrow transplantation 20111101

• Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111101

• Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.

  European journal of haematology 20111101

• Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.

  Clinical immunology (Orlando, Fla.) 20111101

• Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings.

  Journal of medical virology 20111101

• Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.

  Cytometry. Part B, Clinical cytometry 20111101

• Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

  Clinical and experimental immunology 20111101

• Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.

  Journal of pediatric surgery 20111101

• An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia.

  Blood 20111013

• Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).

  Bone marrow transplantation 20111001

• Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111001

• Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20111001

• Prolonged progression-free survival in patients with chronic lymphocytic leukemia receiving granulocyte colony-stimulating factor during treatment with fludarabine, cyclophosphamide, and rituximab.

  Annals of hematology 20111001

• Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.

  Leukemia & lymphoma 20111001

• Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.

  Leukemia & lymphoma 20111001

• Treatment strategies in patients with core-binding factor acute myeloid leukemia.

  Current oncology reports 20111001

• A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.

  British journal of haematology 20111001

• Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.

  Cancer gene therapy 20111001

• Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.

  International journal of hematology 20111001

• Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997.

  Blood 20110929

• Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

  Blood 20110922

• Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110910

• A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

  Cancer chemotherapy and pharmacology 20110901

• Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110901

• Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110901

• Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

  Haematologica 20110901

• Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.

  Blood 20110901

• Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.

  British journal of haematology 20110901

• Progress in the treatment of chronic lymphocytic leukemia: results of the German CLL8 trial.

  Expert review of anticancer therapy 20110901

• Comment on research report by Gruson and colleagues, this issue.

  Journal of the peripheral nervous system : JPNS 20110901

• Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.

  Journal of the peripheral nervous system : JPNS 20110901

• Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

  Blood 20110825

• Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.

  Blood 20110825

• Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.

  Blood 20110825

• Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.

  Bone marrow transplantation 20110801

• Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110801

• NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110801

• A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).

  Pediatric blood & cancer 20110801

• Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20110801

• Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

  Cancer gene therapy 20110801

• Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.

  Leukemia research 20110801

• Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110801

• Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20110801

• [The comparison of fludarabine or antithymocyte globulin based non-myeloablative conditioning regimen for haematologic diseases with graft-versus-host disease].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110801

• ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.

  Blood 20110728

• Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110715

• Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.

  British journal of cancer 20110712

• High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Unrelated donor transplantation for acute myelogenous leukemia in first remission.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110701

• Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.

  Annals of hematology 20110701

• Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.

  Leukemia research 20110701

• Targeting the disturbed redox equilibrium in chronic lymphocytic leukemia by novel reactive oxygen species-catalytic 'sensor/effector' compounds.

  Leukemia & lymphoma 20110701

• New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.

  American journal of hematology 20110701

• A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.

  British journal of haematology 20110701

• Rituximab in chronic lymphocytic leukemia.

  Advances in therapy 20110701

• Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

  Blood 20110616

• [Practical considerations and questions in the treatment of chronic lymphocytic leukemia].

  Orvosi hetilap 20110612

• A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents.

  Bone marrow transplantation 20110601

• Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110601

• CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.

  Leukemia research 20110601

• STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.

  American journal of physiology. Cell physiology 20110601

• Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.

  Cancer gene therapy 20110601

• Purine analog toxicity in patients with hairy cell leukemia.

  Leukemia & lymphoma 20110601

• Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110601

• Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.

  American journal of hematology 20110601

• Allogeneic stem cell transplantation in follicular lymphoma.

  Best practice & research. Clinical haematology 20110601

• Fludarabine versus chlorambucil: is the debate over?

  Clinical lymphoma, myeloma & leukemia 20110601

• Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

  Journal of immunology (Baltimore, Md. : 1950) 20110515

• Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.

  Cancer 20110515

• Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement.

  International journal of radiation oncology, biology, physics 20110501

• Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia.

  International journal of cancer 20110501

• Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.

  Bone marrow transplantation 20110501

• EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.

  Bone marrow transplantation 20110501

• Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.

  Bone marrow transplantation 20110501

• Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT.

  Bone marrow transplantation 20110501

• Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.

  Bone marrow transplantation 20110501

• Evaluating the impact of antithymocyte globulin on lung function at 1 year after allogeneic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501

• Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501

• Diagnostic and therapeutic challenges.

  Retina (Philadelphia, Pa.) 20110501

• The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110501

• EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab.

  Journal of neurology 20110501

• [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].

  Actas dermo-sifiliograficas 20110501

• How I manage cold agglutinin disease.

  British journal of haematology 20110501

• Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.

  Haematologica 20110501

• Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20110501

• Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated-donors.

  American journal of hematology 20110501

• Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.

  Health technology assessment (Winchester, England) 20110501

• Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation.

  Bone marrow transplantation 20110401

• Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.

  Leukemia research 20110401

• Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.

  Leukemia research 20110401

• Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.

  Leukemia & lymphoma 20110401

• Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110401

• Reduced-intensity conditioning by fludarabine/busulfan without additional irradiation or T-cell depletion leads to low non-relapse mortality in unrelated bone marrow transplantation.

  International journal of hematology 20110401

• Inhibitory effect of leptin on rosiglitazone-induced differentiation of primary adipocytes prepared from TallyHO/Jng mice.

  Biochemical and biophysical research communications 20110325

• Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

  Blood 20110317

• Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.

  Journal of proteome research 20110304

• Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110301

• Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110301

• Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).

  Annals of hematology 20110301

• APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.

  European journal of haematology 20110301

• Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.

  Biochemical pharmacology 20110301

• A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

  British journal of haematology 20110301

• Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).

  Leukemia & lymphoma 20110301

• Antithymocyte globulin-induced acute lung injury during transplantation for aplastic anemia.

  Journal of pediatric hematology/oncology 20110301

• Early initial therapy of advanced follicular lymphoma: the need for vigilance.

  Leukemia & lymphoma 20110301

• Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.

  Journal of the National Cancer Institute 20110216

• ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.

  Oncogene 20110210

• Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.

  Annals of hematology 20110201

• Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age.

  Haematologica 20110201

• Alloreactive natural killer cells promote haploidentical hematopoietic stem cell transplantation by expansion of recipient-derived CD4(+) CD25(+) regulatory T cells.

  Transplant international : official journal of the European Society for Organ Transplantation 20110201

• The RNA activator ds-p21 potentiates the cytotoxicity induced by fludarabine in Dohh2 cells.

  Oligonucleotides 20110201

• Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications.

  International journal of hematology 20110201

• Allogeneic hematopoietic stem cell transplant after intravenous busulfan and fludarabine conditioning.

  Leukemia & lymphoma 20110201

• Personalizing treatment for chronic lymphocytic leukemia.

  Expert review of hematology 20110201

• Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

  Expert review of anticancer therapy 20110201

• [A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients].

  Zhongguo shi yan xue ye xue za zhi 20110201

• [A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110201

• The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.

  Biochemical pharmacology 20110115

• Synthesis and biological properties of the cytotoxic 14-membered macrolides aspergillide A and B.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20110110

• Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

  Blood 20110106

• Comparison of donor chimerism following myeloablative and nonmyeloablative allogeneic hematopoietic SCT.

  Bone marrow transplantation 20110101

• High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

  Bone marrow transplantation 20110101

• Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.

  Bone marrow transplantation 20110101

• Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20110101

• Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome.

  Annals of hematology 20110101

• Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

  Cancer immunology, immunotherapy : CII 20110101

• Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

  Leukemia & lymphoma 20110101

• Refractory Bartonella quintana bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia.

  Journal of medical microbiology 20110101

• U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

  The oncologist 20110101

• A transient IgE monoclonal protein in a child.

  Annals of clinical biochemistry 20110101

• FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.

  Journal of experimental & clinical cancer research : CR 20110101

• [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20110101

• Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

  Journal of hematology & oncology 20110101

• [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].

  Gaceta sanitaria 20110101

• Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab.

  BMC nephrology 20110101

• Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

  Neoplasma 20110101

• Significant oral graft-versus-host disease after allogeneic stem cell transplantation with the FLU/MEL conditioning regimen.

  Medical science monitor : international medical journal of experimental and clinical research 20110101

• Atypical cytogenetics in therapy-related myelodysplastic syndrome secondary to indolent B-cell lymphoma.

  Clinical laboratory science : journal of the American Society for Medical Technology 20110101

• Combination treatment of flag with non-pegylated liposomal doxorubicin (MYOCET(TM)) in elderly patients with acute myeloid leukemia: a single center experience.

  International journal of immunopathology and pharmacology 20110101

• Long-term results of non-fludarabine versus fludarabine-based stem cell transplantation without total body irradiation in Fanconi anemia patients.

  Hematology/oncology and stem cell therapy 20110101

• Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.

  Onkologie 20110101

• Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells.

  PloS one 20110101

• The treatment of relapsed refractory chronic lymphocytic leukemia.

  Hematology. American Society of Hematology. Education Program 20110101

• Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.

  Lancet (London, England) 20101211

• CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.

  Bone marrow transplantation 20101201

• Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.

  Gene therapy 20101201

• Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.

  Experimental hematology 20101201

• Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.

  Human pathology 20101201

• Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

  Leukemia & lymphoma 20101201

• Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.

  Leukemia & lymphoma 20101201

• Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.

  Leukemia & lymphoma 20101201

• Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.

  Leukemia 20101201

• Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring.

  Leukemia & lymphoma 20101201

• Continuous sequential infusion of fludarabine and cytarabine for elderly patients with acute myeloid leukaemia secondary to a previously diagnosed myelodysplastic syndrome.

  Hematological oncology 20101201

• The European Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use.

  The oncologist 20101201

• DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.

  Experimental oncology 20101201

• [Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].

  Methods and findings in experimental and clinical pharmacology 20101201

• Effect of FCGR2A and FCGR3A variants on CLL outcome.

  Blood 20101118

• Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.

  Annals of hematology 20101101

• Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome.

  The Journal of allergy and clinical immunology 20101101

• Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20101101

• B-chronic lymphocytic leukemia chemoresistance involves innate and acquired leukemic side population cells.

  Leukemia 20101101

• A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

  Leukemia 20101101

• Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.

  Leukemia & lymphoma 20101101

• Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?

  Leukemia & lymphoma 20101101

• Allogeneic hematopoietic cell transplantation for myelofibrosis: a 10-year experience at single institution.

  American journal of hematology 20101101

• Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.

  Transplantation proceedings 20101101

• Refractory chronic lymphocytic leukemia--new therapeutic strategies.

  Oncotarget 20101101

• High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.

  Blood 20101028

• Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

  Blood 20101021

• Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010

• TP53 mutation and survival in chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101010

• Chronic lymphocytic leukaemia--moving towards cure?

  Lancet (London, England) 20101002

• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  Lancet (London, England) 20101002

• Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20101001

• HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus.

  Journal of hepatology 20101001

• Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.

  Pediatric hematology and oncology 20101001

• The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.

  British journal of haematology 20101001

• Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.

  Leukemia & lymphoma 20101001

• Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.

  Leukemia 20101001

• Current immunochemotherapy strategies in follicular lymphoma.

  Advances in therapy 20101001

• What's new in Waldenström macroglobulinemia.

  Leukemia & lymphoma 20101001

• Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.

  Leukemia & lymphoma 20101001

• Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

  Expert review of anticancer therapy 20101001

• The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.

  Health technology assessment (Winchester, England) 20101001

• Stem cell transplantation using non-myeloablative conditioning regimen with fludarabine for hematological malignancies.

  Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20101001

• Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).

  Cancer 20100915

• Rapid vision loss associated with fludarabine administration.

  Retina (Philadelphia, Pa.) 20100901

• U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100901

• Chemoimmunotherapy of chronic lymphocytic leukemia.

  Nature reviews. Clinical oncology 20100901

• Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity.

  European journal of medicinal chemistry 20100901

• LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

  Leukemia 20100901

• Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.

  American journal of hematology 20100901

• Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20100901

• Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.

  International journal of hematology 20100901

• Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.

  British journal of cancer 20100824

• Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

  Blood 20100812

• Progressive multifocal leukencephalopathy and cerebral toxoplasmosis in a patient with CLL.

  American journal of hematology 20100801

• Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.

  Bone marrow transplantation 20100801

• High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.

  European journal of cancer (Oxford, England : 1990) 20100801

• Auer rod-like inclusions in a low-grade B-cell leukemia.

  Annals of diagnostic pathology 20100801

• [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].

  Orvosi hetilap 20100801

• Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).

  Clinical lymphoma, myeloma & leukemia 20100801

• [Bone marrow failure due to telomere associated gene mutation].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100801

• Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis.

  Blood 20100729

• Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.

  European journal of pharmacology 20100725

• Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710

• Inhibition of STAT1 accelerates bone fracture healing.

  Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20100701

• Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients.

  Leukemia research 20100701

• Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.

  Cancer investigation 20100701

• Haemophagocytic syndrome and Hodgkin's disease variant of Richter's syndrome after fludarabine for CLL.

  European journal of haematology 20100701

• Rhodococcus equi pneumonia in a patient with fludarabine-treated chronic lymphocytic leukemia and CD4-lymphopenia.

  The American journal of the medical sciences 20100701

• Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

  Leukemia 20100701

• Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.

  Leukemia & lymphoma 20100701

• Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.

  Environmental and molecular mutagenesis 20100701

• Ofatumumab in the treatment of chronic lymphocytic leukemia.

  Drugs of today (Barcelona, Spain : 1998) 20100701

• HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

  Blood 20100624

• T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.

  Medical oncology (Northwood, London, England) 20100601

• Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.

  Molecular and cellular biochemistry 20100601

• Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100601

• Regulatory T cell as a target for cancer therapy.

  Archivum immunologiae et therapiae experimentalis 20100601

• Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.

  Haematologica 20100601

• Inefficient dystrophin expression after cord blood transplantation in Duchenne muscular dystrophy.

  Muscle & nerve 20100601

• [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].

  Zhongguo shi yan xue ye xue za zhi 20100601

• Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100510

• Fludarabine-based reduced intensity conditioning transplants have a higher incidence of cytomegalovirus reactivation compared with myeloablative transplants.

  Bone marrow transplantation 20100501

• All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

  The Journal of biological chemistry 20100430

• Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100410

• A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.

  Biomedical chromatography : BMC 20100401

• [Brucella bacteremia reactivation 70 years after the primary infection].

  Medecine et maladies infectieuses 20100401

• Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.

  Leukemia research 20100401

• Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis.

  Clinical and experimental dermatology 20100401

• The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100401

• Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.

  American journal of hematology 20100401

• Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.

  American journal of hematology 20100401

• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100401

• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100401

• Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.

  American journal of hematology 20100401

• Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.

  Journal of pediatric hematology/oncology 20100401

• Therapeutic strategy in p47-phox deficient chronic granulomatous disease presenting as inflammatory bowel disease.

  The Journal of allergy and clinical immunology 20100401

• [Female case of successful engraftment after PBSCT from her HLA-haploidentical son for severe aplastic anemia during maintenance peritoneal dialysis].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20100401

• Incidence and susceptibility to therapy-related myeloid neoplasms.

  Chemico-biological interactions 20100319

• HLA-matched allo-SCT after reduced intensity conditioning with fludarabine/CY in patients with metastatic breast cancer.

  Bone marrow transplantation 20100301

• Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.

  Leukemia research 20100301

• Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.

  Bone marrow transplantation 20100301

• Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20100301

• The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.

  European journal of haematology 20100301

• Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.

  British journal of haematology 20100301

• R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia.

  Leukemia 20100301

• CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.

  Experimental hematology 20100301

• Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.

  Leukemia 20100301

• Natural pregnancy and delivery after unrelated bone marrow transplantation using fludarabine-based regimen in a Fanconi anemia patient.

  International journal of hematology 20100301

• A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.

  Leukemia & lymphoma 20100301

• Clinical and imaging features of fludarabine neurotoxicity.

  Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 20100301

• NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100220

• A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.

  Blood 20100204

• Evidence of a clinical response at one yr after reduced-intensity allogeneic hematopoietic stem cell transplantation in heavily pretreated adolescents with aggressive refractory Hodgkin's lymphoma.

  Pediatric transplantation 20100201

• Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.

  Bone marrow transplantation 20100201

• Successful allo-SCT in a Fanconi anemia patient with renal impairment using reduced doses of CY and fludarabine.

  Bone marrow transplantation 20100201

• The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100201

• Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).

  British journal of haematology 20100201

• [Correlation of deoxycytidine kinase gene expression with fludarabine resistance in patients with chronic lymphocytic leukemia].

  Zhongguo shi yan xue ye xue za zhi 20100201

• Drug-induced immune hemolytic anemia.

  Clinical advances in hematology & oncology : H&O 20100201

• Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

  Blood 20100121

• Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100120

• Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation.

  Bone marrow transplantation 20100101

• Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT.

  Bone marrow transplantation 20100101

• Renal dysfunction due to leukemic infiltration of kidneys in a case of chronic lymphocytic leukemia.

  Hemodialysis international. International Symposium on Home Hemodialysis 20100101

• Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia.

  Leukemia 20100101

• Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.

  Biopharmaceutics & drug disposition 20100101

• R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.

  Journal of cellular biochemistry 20100101

• Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation.

  British journal of haematology 20100101

• Low-dose fludarabine increases rituximab cytotoxicity in B-CLL cells by triggering caspases activation in vitro.

  Leukemia & lymphoma 20100101

• New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.

  Leukemia & lymphoma 20100101

• Novel therapeutic approaches in systemic lupus erythematosus.

  Frontiers in bioscience (Scholar edition) 20100101

• Cutaneous Richter's syndrome, prognosis, and clinical, histological and immunohistological patterns: report of four cases and review of the literature.

  Dermatology (Basel, Switzerland) 20100101

• Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.

  Acta haematologica 20100101

• Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab.

  Chemotherapy 20100101

• A rare occurrence of hairy cell leukemia in the Thai population: a case report.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20100101

• [Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].

  Terapevticheskii arkhiv 20100101

• Fludarabine-induced bradycardia in a patient with refractory leukemia.

  Annals of Saudi medicine 20100101

• Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia.

  Molecular cancer 20100101

• MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.

  Molecular cancer 20100101

• Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

  Human antibodies 20100101

• Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (Macaca fascicularis) islet allograft recipients.

  Cell transplantation 20100101

• Use of clofarabine for acute childhood leukemia.

  Biologics : targets & therapy 20100101

• Immune hemolytic anemia associated with drug therapy.

  Blood reviews 20100101

• Biclonal follicular lymphoma: histological, clinical and molecular characteristics.

  Pathology 20100101

• Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia.

  Journal of hematology & oncology 20100101

• Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.

  Acta haematologica 20100101

• Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

  Blood 20091224

• Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

  Blood 20091217

• Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.

  Blood 20091217

• IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.

  Annals of hematology 20091201

• Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.

  Bone marrow transplantation 20091201

• Fludarabine, Cyclophosphamide and Rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia.

  Irish journal of medical science 20091201

• Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.

  British journal of haematology 20091201

• Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab.

  Journal of hepatology 20091201

• Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression.

  Leukemia & lymphoma 20091201

• [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].

  Zhongguo shi yan xue ye xue za zhi 20091201

• In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.

  Internal medicine journal 20091201

• Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.

  Cancer 20091115

• Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.

  Bone marrow transplantation 20091101

• The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

  Leukemia 20091101

• Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.

  Experimental hematology 20091101

• 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091101

• Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.

  American journal of hematology 20091101

• Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091101

• Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091101

• The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.

  Cancer research 20091101

• Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20091101

• First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

  Blood 20091015

• Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.

  Cancer chemotherapy and pharmacology 20091001

• Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.

  Leukemia research 20091001

• Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia.

  Leukemia 20091001

• Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

  Leukemia 20091001

• Diagnosis by sheer coincidence.

  The international journal of cardiovascular imaging 20091001

• Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma.

  Cancer science 20091001

• Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.

  British journal of haematology 20091001

• Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.

  Pancreas 20091001

• Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.

  Leukemia & lymphoma 20091001

• FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.

  American journal of hematology 20091001

• Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20091001

• Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.

  Leukemia & lymphoma 20091001

• The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial.

  Leukemia & lymphoma 20091001

• [Effect of FLAG consolidation therapy on mobilization of autologous peripheral blood stem cells in patients with acute myelogenous leukemia].

  Zhongguo shi yan xue ye xue za zhi 20091001

• [Clinical analysis of 14 patients with lymphoma associated hemophagocytic syndrome].

  Zhongguo shi yan xue ye xue za zhi 20091001

• Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

  Leukemia & lymphoma 20091001

• p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

  Leukemia & lymphoma 20091001

• Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.

  Tennessee medicine : journal of the Tennessee Medical Association 20091001

• Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

  Blood 20090924

• Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.

  Lancet (London, England) 20090912

• Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.

  Pediatric transplantation 20090901

• Chronic lymphocytic leukemia: treatment options for patients with refractory disease.

  Cancer 20090901

• Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?

  British journal of haematology 20090901

• Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090901

• Rituximab for polyneuropathy with IgM monoclonal gammopathy.

  Journal of neurology, neurosurgery, and psychiatry 20090901

• Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.

  Haematologica 20090901

• Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

  Blood 20090820

• Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090820

• Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.

  Leukemia research 20090801

• Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

  Leukemia & lymphoma 20090801

• Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.

  Annals of the New York Academy of Sciences 20090801

• [Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20090801

• [Conditioning regimen containing fludarabine instead of cyclophosphamide for haploidentical hematopoietic stem cell transplantation].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20090801

• Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090715

• Thalidomide induces phosphorylation of histone H2AX and increases rate of apoptosis caused by fludarabine in malignant lymphocytes of chronic lymphocytic leukemia in short-term cell cultures.

  Leukemia research 20090701

• Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.

  Current opinion in hematology 20090701

• Treatment of fludarabine-refractory chronic lymphocytic leukemia.

  Cancer 20090701

• Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.

  Cancer research 20090701

• Better posttransplant outcome with fludarabine based conditioning in multitransfused fanconi anemia patients who underwent peripheral blood stem cell transplantation.

  Journal of pediatric hematology/oncology 20090701

• Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT.

  Leukemia research 20090601

• The combined use of Flu/ATG in nonmyeloablative SCT for severe aplastic anemia with multiple earlier transfusions.

  Bone marrow transplantation 20090601

• A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.

  British journal of haematology 20090601

• Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090601

• The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.

  Journal of Korean medical science 20090601

• [Clinical study on fludarabine combined with cytarabine regimen in the treatment of patients with refractory and relapsed acute myeloid leukemia].

  Zhongguo shi yan xue ye xue za zhi 20090601

• Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.

  Current opinion in oncology 20090601

• Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

  Health technology assessment (Winchester, England) 20090601

• Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.

  International journal of clinical oncology 20090601

• Pentostatin treatment combinations in chronic lymphocytic leukemia.

  Clinical advances in hematology & oncology : H&O 20090601

• Lymphoplasmacytic lymphoma with IgA hypergammaglobulinemia and liver involvement.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090601

• Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.

  Bone marrow transplantation 20090501

• Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.

  Bone marrow transplantation 20090501

• Oxidative stress and delta-ALA-D activity in different conditioning regimens in allogeneic bone marrow transplantation patients.

  Clinical biochemistry 20090501

• Allogeneic hematopoietic stem cell transplantation of patients with FA and high risk features using fludarabine without radiation.

  Pediatric blood & cancer 20090501

• A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

  Leukemia 20090501

• Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.

  Cancer 20090501

• Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.

  European journal of pharmacology 20090501

• Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20090501

• Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.

  Journal of clinical pathology 20090501

• Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

  Blood 20090416

• Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

  Blood 20090402

• Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.

  American journal of hematology 20090401

• Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.

  Leukemia & lymphoma 20090401

• [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].

  Zhongguo shi yan xue ye xue za zhi 20090401

• A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.

  Internal medicine journal 20090401

• A single apheresis procedure in the donor may be enough to complete an allograft using the 'Mexican method' of non-ablative allografting.

  Blood transfusion = Trasfusione del sangue 20090401

• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  Blood 20090319

• Feasibility of a dose-adjusted fludarabine-melphalan conditioning prior autologous stem cell transplantation in a dialysis-dependent patient with mantle cell lymphoma.

  Annals of hematology 20090301

• Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial.

  Leukemia 20090301

• Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.

  Bone marrow transplantation 20090301

• HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling.

  Microvascular research 20090301

• Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.

  American journal of hematology 20090301

• Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.

  American journal of hematology 20090301

• Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.

  Leukemia & lymphoma 20090301

• Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis.

  Leukemia & lymphoma 20090301

• Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.

  Leukemia & lymphoma 20090301

• Assessment of bone marrow response in Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20090301

• Rituximab-based treatments in Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20090301

• Fludarabine-based combination therapies for Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20090301

• A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.

  Cancer chemotherapy and pharmacology 20090201

• Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.

  Leukemia research 20090201

• Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.

  Annals of hematology 20090201

• Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.

  Journal of cancer research and clinical oncology 20090201

• Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.

  Leukemia 20090201

• Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.

  European journal of haematology 20090201

• Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090201

• Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090201

• Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090201

• Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090201

• Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.

  Leukemia & lymphoma 20090201

• Alkylating agents for Waldenstrom's macroglobulinaemia.

  The Cochrane database of systematic reviews 20090121

• Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120

• Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Dasatinib induces a response in chronic lymphocytic leukemia.

  Blood 20090108

• Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures.

  Cancer chemotherapy and pharmacology 20090101

• A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

  Annals of hematology 20090101

• Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.

  Bone marrow transplantation 20090101

• AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.

  Blood 20090101

• Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.

  Immunologic research 20090101

• Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

  Haematologica 20090101

• [First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].

  Presse medicale (Paris, France : 1983) 20090101

• Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.

  British journal of haematology 20090101

• Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

  British journal of haematology 20090101

• Radiosensitization by inhibiting STAT1 in renal cell carcinoma.

  International journal of radiation oncology, biology, physics 20090101

• Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• A Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20090101

• Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen.

  Cytotherapy 20090101

• ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.

  BMC cancer 20090101

• Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.

  PloS one 20090101

• Chronic lymphocytic leukaemia: current first-line therapy.

  Internal medicine journal 20090101

• Fludarabine-based reduced intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with aplastic anemia and fungal infections.

  Clinical transplantation 20090101

• Fludarabine in the treatment of chronic lymphocytic leukemia: a review.

  Therapeutics and clinical risk management 20090101

• FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

  Immunologic research 20090101

• Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20090101

• Update in the management of chronic lymphocytic leukemia.

  Journal of hematology & oncology 20090101

• Long-lasting response of chronic lymphocytic leukemia and multiple sclerosis in a patient treated with oral fludarabine alone.

  Tumori 20090101

• Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.

  Acta dermato-venereologica 20090101

• Immune hemolytic anemia--selected topics.

  Hematology. American Society of Hematology. Education Program 20090101

• State-of-the-art treatment of chronic lymphocytic leukemia.

  Hematology. American Society of Hematology. Education Program 20090101

• The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081215

• A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.

  Pediatric transplantation 20081201

• Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

  Leukemia research 20081201

• Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.

  Hematological oncology 20081201

• Massive swelling of the cervical region: an uncommon manifestation of B cell chronic lymphocytic leukemia.

  Oral and maxillofacial surgery 20081201

• Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.

  Bone marrow transplantation 20081201

• 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

  Bone marrow transplantation 20081201

• Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.

  Haematologica 20081201

• Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

  British journal of haematology 20081201

• Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.

  Molecular cancer research : MCR 20081201

• Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

  Journal of medicinal chemistry 20081113

• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081110

• Non-homologous end joining is the responsible pathway for the repair of fludarabine-induced DNA double strand breaks in mammalian cells.

  Mutation research 20081110

• Leptin inhibits rosiglitazone-induced adipogenesis in murine primary adipocytes.

  Molecular and cellular endocrinology 20081106

• Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.

  Annals of hematology 20081101

• Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization.

  Leukemia 20081101

• Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

  Blood 20081101

• Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia.

  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 20081101

• Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases.

  European journal of haematology 20081101

• p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.

  Blood 20081101

• Images in haematology. Cerebral nocardiosis in a patient with lymphoplasmacytic lymphoma treated with fludarabine.

  British journal of haematology 20081101

• Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.

  Leukemia 20081101

• Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.

  Haematologica 20081101

• Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20081101

• Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20081101

• Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.

  British journal of haematology 20081101

• Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin's lymphoma.

  European journal of medical research 20081027

• Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.

  Transplantation 20081015

• Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients.

  Cancer chemotherapy and pharmacology 20081001

• Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone.

  Leukemia & lymphoma 20081001

• [Chronic lymphocytic leukemia and the related disorders].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20081001

• Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

  Molecular cancer therapeutics 20081001

• Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia.

  Bone marrow transplantation 20081001

• Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.

  Chinese medical journal 20080920

• Imatinib inhibition of fludarabine uptake in T-lymphocytes.

  Cancer chemotherapy and pharmacology 20080901

• Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.

  Leukemia 20080901

• Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.

  Blood 20080901

• Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.

  American journal of hematology 20080901

• Epstein-Barr virus reactivation is a potentially severe complication in chronic lymphocytic leukemia patients with poor prognostic biological markers and fludarabine refractory disease.

  Haematologica 20080901

• Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemia.

  Current oncology reports 20080901

• Pentostatin in chronic lymphocytic leukemia.

  Expert opinion on drug metabolism & toxicology 20080901

• Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080901

• Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: Single-institute experience.

  Pediatric transplantation 20080901

• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  Blood 20080815

• The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes.

  Blood 20080815

• Auto-immune neutropenia associated with metformin in a patient with splenic marginal zone lymphoma.

  Pharmacy world & science : PWS 20080801

• Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.

  American journal of hematology 20080801

• Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome.

  Bone marrow transplantation 20080801

• Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080801

• Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080801

• Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080801

• [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].

  Zhongguo shi yan xue ye xue za zhi 20080801

• Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.

  Leukemia & lymphoma 20080801

• Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

  Blood 20080715

• Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.

  Transplant infectious disease : an official journal of the Transplantation Society 20080701

• Successful bone marrow transplantation in a girl with Fanconi anemia and preterminal renal failure.

  Bone marrow transplantation 20080701

• Comparable engraftment and chimerism kinetics using oral and intravenous fludarabine as part of a reduced intensity conditioning regimen.

  Bone marrow transplantation 20080701

• Selective killing of Mycobacterium avium-infected macrophages by inhibition of phosphorylated signal transducer and activator of transcription type 1.

  The Journal of infectious diseases 20080701

• Comment to: Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93:398-403.

  Haematologica 20080701

• Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080701

• Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

  Blood 20080615

• [Novel medical treatment modalities in hematology].

  Ugeskrift for laeger 20080609

• Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

  Bone marrow transplantation 20080601

• Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies.

  Cellular signalling 20080601

• Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.

  Leukemia 20080601

• Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.

  Leukemia & lymphoma 20080601

• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080601

• Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.

  British journal of haematology 20080601

• Non-MALT marginal zone lymphomas.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.

  Nucleosides, nucleotides & nucleic acids 20080601

• Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.

  Journal of cellular biochemistry 20080515

• CD-34 selected hematopoetic stem cell transplantation from HLA identical family members for fanconi anemia.

  Pediatric blood & cancer 20080501

• Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.

  Annals of hematology 20080501

• IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.

  Blood 20080501

• A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.

  Bone marrow transplantation 20080501

• Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.

  Bone marrow transplantation 20080501

• Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.

  Journal of molecular medicine (Berlin, Germany) 20080501

• Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

  British journal of haematology 20080501

• Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

  Experimental hematology 20080501

• Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20080501

• Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080501

• Fludarabine/intermediate-dose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience.

  International journal of hematology 20080501

• Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.

  Cancer investigation 20080501

• Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols.

  Saudi medical journal 20080501

• Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20080501

• Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.

  Journal of pharmaceutical sciences 20080401

• Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.

  European journal of haematology 20080401

• High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.

  Bone marrow transplantation 20080401

• Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

  The Lancet. Oncology 20080401

• Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080401

• Antibody therapy for chronic lymphocytic leukemia.

  Seminars in hematology 20080401

• Use of TAGVHD warnings in patients receiving purine analogue chemotherapy.

  Transfusion medicine (Oxford, England) 20080401

• Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future.

  Onkologie 20080401

• Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase.

  Onkologie 20080401

• Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

  Cancer 20080315

• Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080315

• Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.

  Pediatric blood & cancer 20080301

• Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine.

  Leukemia 20080301

• Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.

  Leukemia 20080301

• Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.

  Haematologica 20080301

• Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.

  British journal of haematology 20080301

• Phase I trial of nelarabine in indolent leukemias.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma.

  Haematologica 20080301

• High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.

  Haematologica 20080301

• Retreatment with fludarabine and cyclosporine for one case of refractory pure red cell aplasia.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20080301

• [Treatment of refractory severe autoimmune disease by combined therapy with Chinese drug and autohemopoietic stem cell transplantation].

  Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine 20080301

• The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.

  Blood 20080215

• Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia.

  Biochemical pharmacology 20080215

• A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.

  Cancer 20080215

• Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.

  Leukemia research 20080201

• Extramedullary, extranodal lymphoplasmacytic lymphoma with macroglobulinemia: long-term complete remission with fludarabine.

  Annals of hematology 20080201

• Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.

  International journal of radiation oncology, biology, physics 20080201

• Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.

  Bone marrow transplantation 20080201

• Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

  Leukemia 20080201

• Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.

  Cell death and differentiation 20080201

• Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.

  Bone marrow transplantation 20080201

• Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.

  Blood 20080201

• Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen.

  Bone marrow transplantation 20080201

• Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines.

  Blood 20080201

• Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients.

  British journal of haematology 20080201

• Fludarabine based reduced intensity conditioning regimens in children undergoing allogeneic stem cell transplantation for severe aplastic anemia.

  Pediatric transplantation 20080201

• Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080201

• Invasive fungal sinusitis in patients treated with fludarabine.

  The Journal of infection 20080201

• Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080201

• High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080201

• Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20080201

• Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

  Haematologica 20080201

• Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.

  Haematologica 20080201

• High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

  Haematologica 20080201

• Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.

  Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20080201

• BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.

  Blood 20080115

• Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells.

  Transplantation 20080115

• Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080110

• A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.

  Leukemia research 20080101

• Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

  Blood cells, molecules & diseases 20080101

• Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.

  Leukemia research 20080101

• Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080101

• Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.

  Medical oncology (Northwood, London, England) 20080101

• Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.

  Leukemia & lymphoma 20080101

• Waldenström macroglobulinemia of the orbit.

  Ophthalmic plastic and reconstructive surgery 20080101

• Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation.

  International journal of hematology 20080101

• Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.

  Pediatric hematology and oncology 20080101

• Prodrug converting enzyme gene delivery by L. monocytogenes.

  BMC cancer 20080101

• Paradoxical exacerbation of psoriasis during therapy with fludarabine.

  European journal of dermatology : EJD 20080101

• Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.

  Pathobiology : journal of immunopathology, molecular and cellular biology 20080101

• Severe prolonged immunosuppression following fludarabine and rituximab combination therapy.

  Chemotherapy 20080101

• Prognostic impact of combined fludarabine, treosulfan and mitoxantrone resistance profile in childhood acute myeloid leukemia.

  Anticancer research 20080101

• Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression.

  Immunology and cell biology 20080101

• Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.

  American journal of clinical dermatology 20080101

• Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.

  European journal of dermatology : EJD 20080101

• Fludarabine in lymphoproliferative malignancies: a single-centre experience.

  The National medical journal of India 20080101

• Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.

  The Egyptian journal of immunology 20080101

• Have we forgotten the purpose of phase III studies?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071210

• Characterization of graft-versus-leukemia responses in patients treated for advanced chronic lymphocytic leukemia with donor lymphocyte infusions after in vitro T-cell depleted allogeneic stem cell transplantation following reduced-intensity conditioning.

  Leukemia 20071201

• Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.

  Bone marrow transplantation 20071201

• Fludarabine reduces survivability of HepG2 cells through VEGF under hypoxia.

  Archives of biochemistry and biophysics 20071201

• Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071201

• Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo.

  European journal of haematology 20071201

• Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20071201

• Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.

  Leukemia & lymphoma 20071201

• Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia.

  Journal of Korean medical science 20071201

• Switching of donor cells after urgent second cord blood transplantation for suspected graft failure.

  International journal of hematology 20071201

• Graft-versus-myeloma effects in reduced-intensity cord blood transplantation.

  International journal of hematology 20071201

• Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.

  Cancer research 20071115

• Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

  Blood 20071101

• Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.

  Bone marrow transplantation 20071101

• Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.

  Bone marrow transplantation 20071101

• Cerebral toxoplasmosis in a patient with chronic lymphocytic leukaemia treated with fludarabine.

  British journal of haematology 20071101

• Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.

  Bone marrow transplantation 20071101

• Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.

  British journal of haematology 20071101

• Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20071101

• Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.

  Experimental hematology 20071101

• Direct antiglobulin test negative autoimmune haemolytic anaemia associated with fludarabine/cyclophosphamide/rituximab therapy.

  British journal of haematology 20071101

• [MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].

  Journal francais d'ophtalmologie 20071101

• Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).

  International journal of hematology 20071101

• [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].

  Vnitrni lekarstvi 20071101

• Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

  Blood 20071015

• Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.

  Blood 20071015

• Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.

  Leukemia 20071001

• Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.

  American journal of hematology 20071001

• Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial.

  American journal of hematology 20071001

• Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.

  Leukemia 20071001

• Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.

  Haematologica 20071001

• Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.

  British journal of haematology 20071001

• Low-dose oral fludarabine plus cyclophosphamide as first-line treatment in elderly patients with indolent non-Hodgkin lymphoma.

  British journal of haematology 20071001

• A novel regimen incorporating the concomitant administration of fludarabine and alemtuzumab for the treatment of refractory adult acute lymphoblastic leukaemia: a report of three cases.

  British journal of haematology 20071001

• Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.

  Leukemia & lymphoma 20071001

• The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy.

  Leukemia & lymphoma 20071001

• Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.

  Leukemia & lymphoma 20071001

• Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.

  The Netherlands journal of medicine 20071001

• [Curative efficacy of fludarabine combined with rituximab and amifostine on aged patient with B-chronic lymphocytic leukemia].

  Zhongguo shi yan xue ye xue za zhi 20071001

• [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].

  Zhongguo shi yan xue ye xue za zhi 20071001

• Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.

  International journal of hematology 20071001

• The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group.

  Haematologica 20071001

• Irreversible visual loss and optic nerve dysfunction associated with central retinal vein occlusion in Waldenstrom Macroglobulinemia.

  The Medical journal of Malaysia 20071001

• Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.

  Current hematologic malignancy reports 20071001

• Graft versus host disease after stem cell allotransplantation with low-dose total body irradiation, fludarabine, and antithymocyte globulin.

  Transplantation 20070915

• Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.

  British journal of cancer 20070911

• Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.

  Gene therapy 20070901

• Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.

  Bone marrow transplantation 20070901

• New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.

  Bone marrow transplantation 20070901

• Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070901

• Chemoimmunotherapy of chronic lymphocytic leukemia.

  Best practice & research. Clinical haematology 20070901

• Minimal residual disease assessment in chronic lymphocytic leukaemia.

  Best practice & research. Clinical haematology 20070901

• Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).

  Pediatric hematology and oncology 20070901

• CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.

  British journal of haematology 20070901

• Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.

  Haematologica 20070901

• Translocation (4;11)(p12;q23) with rearrangement of FRYL and MLL in therapy-related acute myeloid leukemia.

  Cancer genetics and cytogenetics 20070901

• Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.

  Experimental oncology 20070901

• [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070901

• Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis.

  Oncogene 20070823

• Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

  Blood 20070815

• Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.

  Annals of hematology 20070801

• Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.

  Annals of hematology 20070801

• Alkylator-free conditioning regimen for patients with acquired aplastic anemia, transplanted from genetically identical twins.

  Pediatric transplantation 20070801

• Regurgitation of esophageal mucosa.

  Mayo Clinic proceedings 20070801

• Diffuse large B-cell lymphoma developing following treatment of Waldenstrom's macroglobulinaemia: spontaneous resolution upon cessation of fludarabine.

  Leukemia & lymphoma 20070801

• Combination therapies for previously untreated CLL.

  Lancet (London, England) 20070721

• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

  Lancet (London, England) 20070721

• Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.

  British journal of cancer 20070716

• Fludarabine allows dose reduction for total body irradiation in pediatric hematopoietic stem cell transplantation.

  International journal of radiation oncology, biology, physics 20070715

• T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

  Leukemia research 20070701

• Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation.

  Bone marrow transplantation 20070701

• Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.

  Bone marrow transplantation 20070701

• Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.

  Bone marrow transplantation 20070701

• Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.

  Bone marrow transplantation 20070701

• Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.

  Cancer 20070701

• Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070701

• Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070701

• Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.

  Experimental hematology 20070701

• Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.

  British journal of haematology 20070701

• Dictyostelium discoideum salvages purine deoxyribonucleosides by highly specific bacterial-like deoxyribonucleoside kinases.

  Journal of molecular biology 20070608

• Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.

  American journal of hematology 20070601

• Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.

  Cancer chemotherapy and pharmacology 20070601

• Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation.

  American journal of physiology. Heart and circulatory physiology 20070601

• Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

  Rheumatology (Oxford, England) 20070601

• Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine.

  International journal of oncology 20070601

• Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070601

• Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.

  Hematology (Amsterdam, Netherlands) 20070601

• The beneficial effect of chronic graft-versus-host disease on the clinical outcome of transplantation with fludarabine/busulfan-based reduced-intensity conditioning for patients with de novo myelodysplastic syndrome.

  International journal of hematology 20070601

• Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.

  Leukemia & lymphoma 20070601

• [Reactivation of familial hemophagocytic lymphohistiocytosis after non-myeloablative cord blood stem cell transplantation resulted in the early graft failure].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20070601

• [Chronic lymphoid leukemia and intravenous immunoglobulins].

  La Revue de medecine interne 20070601

• Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.

  Oncogene 20070528

• Management of symptomatic, untreated chronic lymphocytic leukemia.

  Blood reviews 20070501

• Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.

  Cytometry. Part B, Clinical cytometry 20070501

• Allogeneic bone marrow transplantation for Pearson's syndrome.

  Bone marrow transplantation 20070501

• Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway.

  Leukemia 20070501

• Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501

• A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia.

  Journal of the American Academy of Dermatology 20070501

• A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070501

• Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.

  British journal of haematology 20070501

• In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation.

  International journal of hematology 20070501

• Acquired hemophilia in chronic lymphocytic leukemia.

  Leukemia & lymphoma 20070501

• Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.

  Haematologica 20070501

• Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

  Haematologica 20070501

• [Ulcers in a patient with chronic lymphocytic leukemia].

  Actas dermo-sifiliograficas 20070501

• Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.

  Cancer chemotherapy and pharmacology 20070401

• Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.

  Cancer immunology, immunotherapy : CII 20070401

• Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.

  Bone marrow transplantation 20070401

• Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases.

  Bone marrow transplantation 20070401

• Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070401

• Current treatment options in prolymphocytic leukemia.

  Medical science monitor : international medical journal of experimental and clinical research 20070401

• Gene expression signatures that predict radiation exposure in mice and humans.

  PLoS medicine 20070401

• Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.

  Journal of Korean medical science 20070401

• Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation.

  Hematology (Amsterdam, Netherlands) 20070401

• Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.

  Leukemia & lymphoma 20070401

• Unrelated-donor bone marrow transplantation with a conditioning regimen including fludarabine, busulfan, and 4 Gy total body irradiation.

  International journal of hematology 20070401

• Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia.

  Haematologica 20070401

• Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070320

• Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.

  Leukemia research 20070301

• Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).

  Leukemia 20070301

• Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.

  Leukemia 20070301

• Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.

  Clinical and experimental dermatology 20070301

• Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070301

• Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.

  Transplant infectious disease : an official journal of the Transplantation Society 20070301

• Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070301

• Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070301

• Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.

  Haematologica 20070301

• Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.

  British journal of haematology 20070301

• Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.

  Leukemia & lymphoma 20070301

• Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: rituximab as the treatment of choice?

  Leukemia research 20070201

• Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.

  Leukemia research 20070201

• Myelopathy due to intrathecal chemotherapy: magnetic resonance imaging findings.

  Clinical radiology 20070201

• F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan.

  Bone marrow transplantation 20070201

• Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.

  Bone marrow transplantation 20070201

• Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.

  Bone marrow transplantation 20070201

• Fatal leukoencephalopathy after reduced-intensity allogeneic stem cell transplantation.

  Onkologie 20070201

• Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?

  European journal of haematology 20070201

• Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.

  European journal of haematology 20070201

• Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.

  International journal of hematology 20070201

• 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.

  Leukemia & lymphoma 20070201

• Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review.

  Leukemia & lymphoma 20070201

• Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

  Haematologica 20070201

• Cutaneous recall phenomenon at the site of previous doxorubicin extravasation after second-line chemotherapy.

  Journal of the National Cancer Institute 20070117

• Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient.

  Leukemia research 20070101

• Preclinical assessment of curcumin as a potential therapy for B-CLL.

  American journal of hematology 20070101

• Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.

  Blood 20070101

• Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan.

  Annals of hematology 20070101

• STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines.

  International journal of cancer 20070101

• Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.

  British journal of haematology 20070101

• Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.

  Journal of the American Academy of Dermatology 20070101

• Conditioning with fludarabine alone and allogeneic transplantation as a successful rescue therapy for persistent, severe iatrogenic aplasia after relapse of acute myeloid leukemia.

  Bone marrow transplantation 20070101

• Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.

  Journal of clinical pharmacology 20070101

• Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.

  British journal of haematology 20070101

• Double unrelated reduced-intensity umbilical cord blood transplantation in adults.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20070101

• Improved outcome after relapse in children with acute myeloid leukaemia.

  British journal of haematology 20070101

• Atypical cutaneous herpes virus infection associated with fludarabine chemotherapy of lymphoma.

  European journal of dermatology : EJD 20070101

• Advances in CLL.

  Clinical advances in hematology & oncology : H&O 20070101

• Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.

  Acta haematologica 20070101

• Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.

  Haematologica 20070101

• Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia.

  Haematologica 20070101

• Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20070101

• [Anemia in chronic lymphatic leukemia: is erythropoietin the solution?].

  Revista de medicina de la Universidad de Navarra 20070101

• Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia.

  Anticancer research 20070101

• Fludarabine: a review of its use in non-Hodgkin's lymphoma.

  Drugs 20070101

• Paraneoplastic pemphigus associated with fludarabine use.

  Medical oncology (Northwood, London, England) 20070101

• [Visual cortes--is it a concern?].

  Bulletin de la Societe belge d'ophtalmologie 20070101

• [Allogenic transplantation of hemopoietic stem cells in low-intensity regimes in patients with hematological malignancies].

  Terapevticheskii arkhiv 20070101

• [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide].

  Terapevticheskii arkhiv 20070101

• Chronic lymphocytic leukemia masquerading as uveitis.

  Retina (Philadelphia, Pa.) 20070101

• The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.

  Nucleosides, nucleotides & nucleic acids 20070101

• Chronic lymphocytic leukemia in the recent 10 years and treatment effects of Fludarabin.

  Asian Pacific journal of cancer prevention : APJCP 20070101

• Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

  Blood 20061215

• Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

  Blood 20061215

• Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy.

  Neurology 20061212

• Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.

  Leukemia research 20061201

• Characterization of the rat Na+/nucleoside cotransporter 2 and transport of nucleoside-derived drugs using electrophysiological methods.

  American journal of physiology. Cell physiology 20061201

• High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.

  American journal of hematology 20061201

• Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061201

• Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.

  Leukemia & lymphoma 20061201

• Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.

  Haematologica 20061201

• Fludarabine delivery by autologous red blood cells induces macrophage depletion in chronically SIV-infected Sooty Mangabeys.

  Journal of controlled release : official journal of the Controlled Release Society 20061128

• Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens.

  British journal of haematology 20061101

• Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.

  Pediatric transplantation 20061101

• Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine.

  European journal of haematology 20061101

• Treatment-related myelodysplasia following fludarabine combination chemotherapy.

  Haematologica 20061101

• Chronic lymphocytic leukemia: current and emerging treatment approaches.

  Clinical advances in hematology & oncology : H&O 20061101

• Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning.

  Transplantation 20061015

• Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.

  European journal of haematology 20061001

• Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.

  British journal of haematology 20061001

• Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation.

  Bone marrow transplantation 20061001

• Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.

  Bone marrow transplantation 20061001

• Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

  Cancer research 20061001

• Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20061001

• Flow cytometric evaluation of red blood cell chimerism after bone marrow transplantation in Iranian patients: a preliminary study.

  Archives of Iranian medicine 20061001

• Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061001

• Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061001

• Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20061001

• [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].

  Zeitschrift fur Rheumatologie 20060901

• Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

  Cancer 20060901

• Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.

  Bone marrow transplantation 20060901

• High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060901

• Role of fludarabine in hematological malignancies.

  Expert review of anticancer therapy 20060901

• Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20060901

• Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.

  Leukemia & lymphoma 20060901

• Nelarabine: a new purine analog in the treatment of hematologic malignancies.

  Reviews on recent clinical trials 20060901

• Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

  Blood 20060815

• The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.

  Cancer 20060815

• Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.

  Blood 20060801

• Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis.

  Bone marrow transplantation 20060801

• Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine.

  Journal of medical virology 20060801

• Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.

  Cancer treatment reviews 20060801

• Graft failure and severe autoimmune haemolysis following fludarabine-based reduced-intensity matched unrelated donor bone marrow transplantation for severe aplastic anaemia: salvage by second transplant with conventional dose conditioning.

  Bone marrow transplantation 20060801

• Central line-related bacteraemia due to Roseomonas mucosa in a neutropenic patient with acute myeloid leukaemia in Piraeus, Greece.

  Journal of medical microbiology 20060801

• A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060801

• Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060801

• Fludarabine in chronic lymphocytic leukaemia.

  Expert opinion on pharmacotherapy 20060801

• Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia.

  Archives of pathology & laboratory medicine 20060801

• MicroRNAs in leukemia.

  Clinical advances in hematology & oncology : H&O 20060801

• Purine antagonists for chronic lymphocytic leukaemia.

  The Cochrane database of systematic reviews 20060719

• Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation.

  European journal of haematology 20060701

• An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060701

• Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060701

• Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.

  Experimental hematology 20060701

• Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia.

  British journal of haematology 20060701

• High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.

  British journal of haematology 20060701

• [Reduced-intensity cord blood transplantation for adult hematological diseases].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060701

• [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060701

• Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.

  Leukemia & lymphoma 20060701

• A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.

  European journal of haematology 20060601

• Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.

  Cancer 20060601

• Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.

  American journal of hematology 20060601

• Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy.

  American journal of hematology 20060601

• Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.

  British journal of haematology 20060601

• Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.

  Onkologie 20060601

• Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.

  International journal of hematology 20060601

• Diagnosis of a primary testicular lymphoma by echography and magnetic resonance imaging.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20060601

• Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.

  Hematology (Amsterdam, Netherlands) 20060601

• Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.

  Hematology (Amsterdam, Netherlands) 20060601

• Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060520

• Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL).

  Blood 20060515

• MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

  Blood 20060515

• Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.

  Pediatric blood & cancer 20060501

• DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.

  Leukemia 20060501

• Fludarabine induces pro-inflammatory activation of human monocytic cells through a MAPK/ERK pathway.

  International immunopharmacology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.

  British journal of haematology 20060501

• Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.

  International journal of hematology 20060501

• Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.

  International journal of hematology 20060501

• The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.

  The Journal of biological chemistry 20060414

• Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter.

  Gene 20060412

• Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.

  Journal of cellular physiology 20060401

• Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.

  Leukemia research 20060401

• Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.

  Bone marrow transplantation 20060401

• The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia.

  Haematologica 20060401

• Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060401

• Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.

  Seminars in hematology 20060401

• Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.

  American journal of hematology 20060401

• The infectious consequences of rituximab addition to fludarabine-containing regimens.

  Blood 20060401

• [State of the art in the treatment of chronic leukemias].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060401

• PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.

  Chemico-biological interactions 20060325

• Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy.

  Spinal cord 20060301

• Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.

  Bone marrow transplantation 20060301

• Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.

  Cancer 20060301

• Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.

  British journal of haematology 20060301

• Guidelines on the management of Waldenström macroglobulinaemia.

  British journal of haematology 20060301

• Exacerbation of chronic epidural abscess following a fludarabine-based preparative regimen.

  American journal of hematology 20060301

• Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.

  American journal of hematology 20060301

• Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20060301

• [Inhibition effect of fludarabine on the growth of myelodysplastic syndrome cell line MUTZ-1 and its mechanism].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20060301

• F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation.

  Nucleosides, nucleotides & nucleic acids 20060301

• Advances in the treatment of chronic lymphocytic leukemia.

  Current hematologic malignancy reports 20060301

• Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

  Blood 20060201

• Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20060201

• Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.

  Bone marrow transplantation 20060201

• Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.

  Bone marrow transplantation 20060201

• Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion.

  European journal of haematology 20060201

• Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

  Bone marrow transplantation 20060201

• Treatment of refractory fludarabine induced autoimmune haemolytic with the anti-CD20 monoclonal antibody rituximab.

  Clinical and laboratory haematology 20060201

• Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060201

• Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia.

  Apoptosis : an international journal on programmed cell death 20060201

• [Effect of inhibitors of signal transducer and activator of transcription-1/3 on expression of tumor necrosis factor-alpha induced by high mobility group box-1 protein inflammatory response in rat peritoneal macrophages].

  Zhonghua wai ke za zhi [Chinese journal of surgery] 20060201

• Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060120

• A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.

  Cancer 20060115

• Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

  Blood 20060101

• Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2.

  Drug metabolism and disposition: the biological fate of chemicals 20060101

• A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.

  Molecular pharmacology 20060101

• Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.

  Leukemia & lymphoma 20060101

• Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.

  European journal of haematology 20060101

• The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060101

• Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

  Japanese journal of clinical oncology 20060101

• Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.

  Acta haematologica 20060101

• Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.

  International journal of hematology 20060101

• Fludarabine induced autoimmune haemolytic anaemia in a patient with chronic lymphocytic leukaemia.

  JPMA. The Journal of the Pakistan Medical Association 20060101

• [Allogeneic stem cell transplantation with fludarabine/melphalan (non-TBI and non-BU/CY) for patients aged 50 or more].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060101

• Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• [Fever and dyspnea in a patient with chronic lymphatic leukemia under treatment with fludarabine].

  Enfermedades infecciosas y microbiologia clinica 20060101

• Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine.

  Nucleosides, nucleotides & nucleic acids 20060101

• [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].

  Terapevticheskii arkhiv 20060101

• IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.

  American journal of therapeutics 20060101

• High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission.

  Medical oncology (Northwood, London, England) 20060101

• Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.

  Nucleosides, nucleotides & nucleic acids 20060101

• Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051220

• The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.

  Cancer 20051215

• OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action.

  Journal of the National Cancer Institute 20051207

• Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma.

  Bone marrow transplantation 20051201

• Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

  Bone marrow transplantation 20051201

• Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas.

  Leukemia & lymphoma 20051201

• Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.

  European journal of haematology 20051201

• Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.

  Clinical transplantation 20051201

• Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051201

• Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.

  Haematologica 20051201

• [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].

  Ai zheng = Aizheng = Chinese journal of cancer 20051201

• Significance of VH genes mutation status for prognosis of CLL patients.

  Experimental oncology 20051201

• Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).

  Blood 20051115

• An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning.

  Transplantation 20051115

• Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

  Blood 20051101

• FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.

  Annals of hematology 20051101

• Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.

  Leukemia 20051101

• Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.

  Leukemia & lymphoma 20051101

• Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.

  Clinical lymphoma & myeloma 20051101

• [Second nonmyeloablative allogeneic peripheral blood stem cell transplantation with more immunosuppressive conditioning regimen for the late graft failure of the patient with acute myeloid leukemia].

  Fukuoka igaku zasshi = Hukuoka acta medica 20051101

• Richter's syndrome--the downside of fludarabine?

  Leukemia research 20051001

• Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.

  Leukemia research 20051001

• Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.

  Leukemia 20051001

• Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).

  International journal of oncology 20051001

• Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20051001

• Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.

  Japanese journal of clinical oncology 20051001

• Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation.

  British journal of haematology 20051001

• High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.

  Therapeutic drug monitoring 20051001

• Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20051001

• Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

  British journal of haematology 20051001

• Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

• [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].

  Deutsche medizinische Wochenschrift (1946) 20050923

• Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

  Blood 20050915

• Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

  Blood 20050901

• Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation.

  Leukemia & lymphoma 20050901

• 'Specific' cutaneous infiltrate of B-cell chronic lymphocytic leukemia at the site of a florid herpes simplex infection.

  Journal of cutaneous pathology 20050901

• Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning.

  British journal of haematology 20050901

• Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.

  Clinical lymphoma & myeloma 20050901

• [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].

  Orvosi hetilap 20050821

• Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820

• [Treatment of refractory and relapsed acute lymphocytic leukemia in adults].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20050818

• Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.

  Bone marrow transplantation 20050801

• Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.

  American journal of hematology 20050801

• 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.

  British journal of haematology 20050801

• The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.

  Blood 20050715

• Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.

  Cancer 20050715

• Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.

  Annals of hematology 20050701

• An evaluation of busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.

  Japanese journal of clinical oncology 20050701

• Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature.

  American journal of hematology 20050701

• Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20050701

• Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia.

  Leukemia & lymphoma 20050701

• Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia.

  Leukemia & lymphoma 20050701

• Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.

  British journal of haematology 20050701

• A highly sensitive high-performance liquid chromatography-mass spectrometry method for quantification of fludarabine triphosphate in leukemic cells.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050625

• Changing the way we think about chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

• Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.

  Blood 20050615

• Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway.

  Biochemical and biophysical research communications 20050603

• Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

  Blood 20050601

• Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.

  Leukemia 20050601

• Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050601

• CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors.

  Bone marrow transplantation 20050601

• Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure.

  European journal of haematology 20050601

• Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.

  Cancer treatment reviews 20050601

• Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

  British journal of haematology 20050601

• Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050601

• Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20050601

• An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.

  Clinical and laboratory haematology 20050601

• Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.

  Annals of diagnostic pathology 20050601

• Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia.

  Haematologica 20050601

• Economic assessment on the management of chronic lymphocytic leukaemia.

  Expert opinion on pharmacotherapy 20050601

• The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.

  Clinical lymphoma 20050601

• FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.

  JPMA. The Journal of the Pakistan Medical Association 20050601

• Apoptosis of peripheral human blood lymphocytes induced by physical-chemical influences and generation of reactive oxygen species.

  Annals of the New York Academy of Sciences 20050601

• Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

  International journal of hematology 20050601

• Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

  European journal of pharmacology 20050509

• Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.

  Annals of hematology 20050501

• Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.

  Bone marrow transplantation 20050501

• Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity.

  Bone marrow transplantation 20050501

• Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.

  Haematologica 20050501

• Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.

  Haematologica 20050501

• Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes.

  The Journal of biological chemistry 20050422

• Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.

  Annals of hematology 20050401

• Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.

  Leukemia research 20050401

• Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.

  Bone marrow transplantation 20050401

• Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.

  European journal of haematology 20050401

• Inefficiency of high-dose G-CSF alone as second mobilization regimen in fludarabin-cyclophosphamide-treated CLL patients who failed to mobilize after chemotherapy and G-CSF.

  Bone marrow transplantation 20050401

• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050401

• p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.

  British journal of haematology 20050401

• Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.

  British journal of haematology 20050401

• Five-month marrow aplasia in a child with refractory acute myeloid leukemia: successful management with continuous granulocyte support and reduced-intensity conditioning followed by matched unrelated bone marrow transplantation.

  Journal of pediatric hematology/oncology 20050401

• Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin.

  Stem cells and development 20050401

• Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.

  Leukemia & lymphoma 20050401

• Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.

  Blood 20050315

• Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB.

  The Journal of biological chemistry 20050311

• Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.

  Blood 20050301

• Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia.

  Leukemia & lymphoma 20050301

• Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning.

  Bone marrow transplantation 20050301

• Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.

  Bone marrow transplantation 20050301

• Fludarabine: risk factor for aggressive behaviour of squamous cell carcinoma of the skin?

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.

  Annals of oncology : official journal of the European Society for Medical Oncology 20050301

• Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis.

  British journal of haematology 20050301

• Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050301

• Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation.

  Bone marrow transplantation 20050301

• [Current and new therapeutic strategies in acute myeloid leukemia].

  Gan to kagaku ryoho. Cancer & chemotherapy 20050301

• Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.

  Clinical lymphoma 20050301

• [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].

  Bulletin du cancer 20050301

• [News in therapeutic management of chronic lymphoid leukemia].

  Bulletin du cancer 20050301

• High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia.

  International journal of cancer 20050220

• Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).

  Bone marrow transplantation 20050201

• Successful bone marrow transplantation in a patient with c-mpl-mutated congenital amegakaryocytic thrombocytopenia from a carrier donor.

  Pediatric transplantation 20050201

• Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050201

• The role of mitoxantrone in the treatment of indolent lymphomas.

  The oncologist 20050201

• Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.

  Haematologica 20050201

• Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.

  Haematologica 20050201

• Peripheral blood stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia.

  Stem cells and development 20050201

• Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20050201

• Lymphoma: diagnosis, staging, natural history, and treatment strategies.

  Seminars in oncology 20050201

• Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations.

  Blood 20050115

• Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

  Blood 20050101

• Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.

  Leukemia 20050101

• Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.

  Bone marrow transplantation 20050101

• Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.

  Haematologica 20050101

• PNP with Waldenström's macroglobulinaemia.

  Clinical and experimental dermatology 20050101

• Fludarabine-based conditioning used in successful bone marrow transplantation from an unrelated donor in a heavily transfused patient with severe aplastic anemia.

  International journal of hematology 20050101

• Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).

  The pharmacogenomics journal 20050101

• In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.

  Neoplasma 20050101

• Analysis of 1H NMR-detectable mobile lipid domains for assessment of apoptosis induced by inhibitors of DNA synthesis and replication.

  Cell biology international 20050101

• Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?

  Anticancer research 20050101

• Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.

  Neoplasma 20050101

• Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.

  Annals of the New York Academy of Sciences 20050101

• Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.

  Roczniki Akademii Medycznej w Bialymstoku (1995) 20050101

• [Progress and perspectives in the treatment of systemic lupus erythematosus].

  Przeglad lekarski 20050101

• [Mantle cell lymphoma mimicking chronic lymphocytic leukemia].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20050101

• Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.

  Oncogene 20041216

• Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.

  Blood 20041201

• Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.

  Leukemia 20041201

• Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia.

  Bone marrow transplantation 20041201

• Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.

  Bone marrow transplantation 20041201

• Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.

  Bone marrow transplantation 20041201

• VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.

  European journal of haematology 20041201

• The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.

  European journal of haematology 20041201

• The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.

  International journal of oncology 20041201

• Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041201

• Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.

  Haematologica 20041201

• Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.

  Haematologica 20041201

• A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.

  Haematologica 20041201

• Effect of fludarabine on leukocyte functions.

  Chemotherapy 20041201

• Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion.

  Cell cycle (Georgetown, Tex.) 20041201

• Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia.

  Leukemia & lymphoma 20041201

• Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.

  Saudi medical journal 20041201

• Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.

  Oncogene 20041125

• The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

  Blood 20041115

• Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.

  Annals of hematology 20041101

• A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.

  Cancer 20041101

• Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.

  Leukemia 20041101

• Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.

  Biochemical pharmacology 20041101

• Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

  British journal of haematology 20041101

• Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041101

• Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.

  Leukemia & lymphoma 20041101

• Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect.

  Leukemia & lymphoma 20041101

• Conditioning regimen of melphalan, fludarabine and total body irradiation in unmanipulated HLA haploidentical stem cell transplantation based on feto-maternal tolerance.

  Internal medicine (Tokyo, Japan) 20041101

• The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.

  Folia morphologica 20041101

• Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells.

  Blood 20041015

• Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

  Blood 20041015

• A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20041015

• Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.

  European journal of haematology 20041001

• Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.

  Leukemia & lymphoma 20041001

• Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.

  Leukemia & lymphoma 20041001

• Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20041001

• Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041001

• [Establishment of nonmyeloablative allogeneic stem cell transplantation model in H-2 haploidentical mice and its related study].

  Zhongguo shi yan xue ye xue za zhi 20041001

• Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.

  Nucleosides, nucleotides & nucleic acids 20041001

• Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning.

  Blood 20040915

• The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.

  Cancer research 20040915

• Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

  Blood 20040901

• Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20040901

• Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

  Leukemia & lymphoma 20040901

• BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.

  Leukemia 20040901

• The role of fludarabine in the treatment of follicular and mantle cell lymphoma.

  Cancer 20040901

• [New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].

  Orvosi hetilap 20040829

• Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.

  Neurology 20040810

• Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

  Blood 20040801

• Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.

  Bone marrow transplantation 20040801

• Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.

  European journal of haematology 20040801

• Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.

  Cancer biology & therapy 20040801

• Fatal peripheral neuropathy following FLA chemotherapy.

  Clinical and laboratory haematology 20040801

• Successful reduced-intensity allogeneic transplantation utilizing a fludarabine-based preparative regimen in a patient with chronic lymphocytic leukaemia and a history of fludarabine-associated autoimmune haemolytic anaemia.

  British journal of haematology 20040801

• Cytopenia and hematopoietic recovery after low intensity conditioning transplants.

  Croatian medical journal 20040801

• Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism.

  Arthritis and rheumatism 20040801

• The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.

  Leukemia 20040701

• Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.

  Bone marrow transplantation 20040701

• Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.

  Leukemia research 20040701

• Acute renal failure after nonmyeloablative hematopoietic cell transplantation.

  Journal of the American Society of Nephrology : JASN 20040701

• 9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells.

  Molecular pharmacology 20040701

• Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.

  Bone marrow transplantation 20040701

• Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.

  Bone marrow transplantation 20040701

• Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia.

  Leukemia & lymphoma 20040701

• Advances in the diagnosis and treatment of chronic lymphocytic leukemia.

  Clinical advances in hematology & oncology : H&O 20040701

• Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.

  Cancer 20040615

• Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.

  Bone marrow transplantation 20040601

• Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection.

  Blood 20040601

• Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040601

• Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.

  Haematologica 20040601

• Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.

  Leukemia & lymphoma 20040601

• Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.

  Leukemia & lymphoma 20040601

• High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.

  The Korean journal of internal medicine 20040601

• Hypoxia/re-oxygenation-induced, redox-dependent activation of STAT1 (signal transducer and activator of transcription 1) confers resistance to apoptotic cell death via hsp70 induction.

  The Biochemical journal 20040515

• Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.

  Cancer 20040515

• Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.

  Cancer 20040515

• Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

  Blood 20040501

• Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.

  Leukemia 20040501

• Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.

  Bone marrow transplantation 20040501

• High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.

  Bone marrow transplantation 20040501

• Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.

  Leukemia research 20040501

• Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.

  Leukemia research 20040501

• Paraneoplastic pemphigus secondary to fludarabine evolving into unusual oral pemphigus vegetans.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20040501

• Distinct clonal origin in two cases of Hodgkin's lymphoma variant of Richter's syndrome associated With EBV infection.

  The American journal of surgical pathology 20040501

• Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20040501

• The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

  Blood 20040415

• Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.

  Annals of hematology 20040401

• Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.

  Bone marrow transplantation 20040401

• Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line.

  Molecular pharmacology 20040401

• The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

  Cancer research 20040401

• Aspergillus fumigatus: a rare cause of vertebral osteomyelitis.

  Haematologica 20040401

• [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases].

  Ai zheng = Aizheng = Chinese journal of cancer 20040401

• Transient absence of hepatic uptake on gallium-67 scintigraphy following fludarabine therapy.

  Clinical nuclear medicine 20040401

• Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.

  Croatian medical journal 20040401

• A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.

  Leukemia research 20040401

• Treatment of chronic lymphocytic leukemia.

  Seminars in oncology 20040401

• Fludarabine- and cyclophosphamide-based nonmyeloablative conditioning regimen for transplantation of chronic granulomatous disease: possible correlation with prolonged pure red cell aplasia.

  International journal of hematology 20040401

• [Waldenstrom macroglobulinemia].

  Praxis 20040331

• Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.

  Blood 20040301

• Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.

  Bone marrow transplantation 20040301

• Reversible acute renal failure following single administration of fludarabine.

  Bone marrow transplantation 20040301

• [Reduced intensity stem cell transplantation for metastatic renal cell carcinoma].

  Nihon Hinyokika Gakkai zasshi. The japanese journal of urology 20040301

• Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

  Leukemia research 20040201

• Nonmyeloablative stem cell transplantation for lymphoma.

  Seminars in oncology 20040201

• [Drug-resistant B cell chronic lymphocytic leukemia safely treated with rituximab to control leukemic cell increment and platelet transfusion dependence].

  Gan to kagaku ryoho. Cancer & chemotherapy 20040201

• Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.

  Seminars in oncology 20040201

• High dose chlorambucil in the treatment of lymphoid malignancies.

  Leukemia & lymphoma 20040201

• Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

  Blood 20040115

• Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

  Blood 20040115

• Simple and sensitive method for quantification of fludarabine triphosphate intracellular concentration in leukemic cells using isocratic liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

  Blood 20040101

• Post-transcriptional regulation of inducible nitric oxide synthase in chronic lymphocytic leukemia B cells in pro- and antiapoptotic culture conditions.

  Leukemia 20040101

• Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

  Leukemia 20040101

• Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.

  British journal of haematology 20040101

• Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.

  British journal of haematology 20040101

• Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.

  Current hematology reports 20040101

• Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Fludarabine-induced hemolytic anemia: successful treatment by rituximab.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.

  Gynecologic oncology 20040101

• Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20040101

• Successful treatment with nonmyeloablative allogeneic hematopoietic stem cell transplantation in a patient with acute myeloid leukemia complicated with pulmonary infection.

  International journal of hematology 20040101

• Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.

  Leukemia & lymphoma 20040101

• Fludarabine in chronic lymphocytic leukemia and other hematological malignancies: progress in treatment. Fludarabine supplement.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Use of fludarabine in the treatment of acute myeloid leukemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Treatment of hematological malignancies with allogeneic nonmyeloablative stem cell transplantation: conditioning regimens with fludarabine.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.

  Annals of hematology 20040101

• Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia.

  The Annals of pharmacotherapy 20040101

• Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.

  Acta haematologica 20040101

• Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.

  BMC pharmacology 20040101

• A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Fludarabine as the possible cause of acute myelofibrosis.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Reconstructing immunity after allogeneic transplantation.

  Immunologic research 20040101

• Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

  Journal of immunotherapy (Hagerstown, Md. : 1997) 20040101

• Nonmyeloablative stem cell transplantation in patients with ALL and AML results in low nonrelapse mortality despite high rate of infections and GVHD.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Purine analogs in leukemia.

  Advances in pharmacology (San Diego, Calif.) 20040101

• Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.

  The hematology journal : the official journal of the European Haematology Association 20040101

• Effects of fludarabine treatment on murine lupus nephritis.

  Lupus 20040101

• [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].

  Voprosy onkologii 20040101

• Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.

  Cancer chemotherapy and pharmacology 20031201

• In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine.

  Biochemical pharmacology 20031201

• Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.

  Clinical and laboratory haematology 20031201

• Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus.

  Transfusion 20031201

• Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.

  International journal of clinical oncology 20031201

• Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.

  Haematologica 20031201

• [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].

  Ai zheng = Aizheng = Chinese journal of cancer 20031201

• B-cell lymphoproliferative syndrome and peripheral blood CD20+ cells expansion after hematopoietic stem cell transplantation: association with fludarabine and anti-thymocyte globulin containing conditioning regimen.

  Transplantation proceedings 20031201

• [Hairy cell leukemia: report on one case with survival for 10 years].

  Zhongguo shi yan xue ye xue za zhi 20031201

• 45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.

  Clinical lymphoma 20031201

• Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.

  Leukemia & lymphoma 20031201

• [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].

  Nederlands tijdschrift voor geneeskunde 20031122

• Involvement of p53 in alpha4beta1 integrin-mediated resistance of B-CLL cells to fludarabine.

  Biochemical and biophysical research communications 20031121

• Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

  Blood 20031115

• Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.

  Oncogene 20031113

• Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression.

  Journal of leukocyte biology 20031101

• The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.

  Bone marrow transplantation 20031101

• Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.

  Annals of the rheumatic diseases 20031101

• Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.

  Haematologica 20031101

• Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation.

  British journal of haematology 20031101

• Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.

  Leukemia & lymphoma 20031101

• Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

  Leukemia research 20031001

• Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.

  Bone marrow transplantation 20031001

• The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20031001

• Fludarabine-related myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031001

• Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin.

  Leukemia 20031001

• Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

  Journal of pediatric hematology/oncology 20031001

• Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases.

  Experimental hematology 20031001

• Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

• [Modified FLAG regimen in the management of refractory acute myeloid leukemia].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20031001

• Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20031001

• Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.

  Leukemia & lymphoma 20031001

• Fatal fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia.

  Leukemia & lymphoma 20031001

• Fludarabine induced immune thrombocytopenia in a patient with CD5 positive B cell chronic lymphocytic leukemia.

  JPMA. The Journal of the Pakistan Medical Association 20031001

• [Pressure pain in the left epigastrium: blood picture provides diagnosis. Chronic lymphatic leukemia].

  MMW Fortschritte der Medizin 20030925

• HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

  Blood 20030915

• Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia.

  Blood 20030915

• Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

  Blood 20030901

• Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.

  Cancer chemotherapy and pharmacology 20030901

• Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.

  Annals of hematology 20030901

• Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.

  Bone marrow transplantation 20030901

• A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.

  Bone marrow transplantation 20030901

• A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030901

• [Non-myeloablative or reduced intensity stem cell transplantation preparative regimens].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Mini-transplantation from HLA-mismatched donors].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Mini-transplantation from cord blood].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Reduced-intensity stem cell transplantation (RIST) for lymphoproliferative diseases].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Non-myeloablative stem cell transplantation for non-malignant hematologic disorders].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Gastrointestinal cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• [Nonmyeloablative allogeneic peripheral blood stem cell transplantation of renal cell carcinoma].

  Nihon rinsho. Japanese journal of clinical medicine 20030901

• The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.

  Leukemia & lymphoma 20030901

• Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.

  Blood 20030801

• Bilateral optic disc swelling as the presenting sign of Waldenström's macroglobulinaemia.

  Acta ophthalmologica Scandinavica 20030801

• Allogeneic hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria.

  European journal of haematology 20030801

• A novel t(15;17) translocation in acute myeloid leukaemia not associated with PML/RARalpha rearrangement.

  Clinical and laboratory haematology 20030801

• Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.

  Bone marrow transplantation 20030801

• Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030801

• Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030801

• Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro.

  Haematologica 20030801

• Early reappearance of primary solid cancer in patients treated with purine analogs.

  Journal of chemotherapy (Florence, Italy) 20030801

• [Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20030801

• [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20030801

• Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.

  Blood 20030715

• Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

  Blood 20030715

• Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030715

• [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].

  MMW Fortschritte der Medizin 20030710

• Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.

  European journal of haematology 20030701

• Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.

  Bone marrow transplantation 20030701

• Fludarabine versus cyclophosphamide, vincristine, and prednisone in recurrent low-grade lymphomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030701

• Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030701

• Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030701

• Hepatitis B virus reactivation during fludarabine therapy in non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20030701

• Effects of etoposide and fludarabine in subtoxic doses on karyotype of human malignant lymphoid Namalwa cells.

  Bulletin of experimental biology and medicine 20030701

• Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia.

  The Journal of the Association of Physicians of India 20030701

• [Evidence-based therapy for chronic leukemia].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20030610

• Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.

  Annals of hematology 20030601

• Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.

  Hematology (Amsterdam, Netherlands) 20030601

• Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study.

  European journal of haematology 20030601

• Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.

  Leukemia 20030601

• Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.

  Bone marrow transplantation 20030601

• Mechanism of action of purine analogues in chronic lymphocytic leukaemia.

  British journal of haematology 20030601

• Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand.

  British journal of haematology 20030601

• Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

  Leukemia & lymphoma 20030601

• Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030515

• Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?

  Leukemia research 20030501

• Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.

  The Annals of pharmacotherapy 20030501

• Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.

  Bone marrow transplantation 20030501

• Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation.

  Bone marrow transplantation 20030501

• Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.

  Leukemia 20030501

• Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia.

  Leukemia 20030501

• Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030415

• Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.

  Cancer 20030401

• Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030401

• Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.

  American journal of hematology 20030401

• Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma.

  Haematologica 20030401

• Bilateral orbital masses in a patient with B-cell chronic lymph.

  Haematologica 20030401

• Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.

  British journal of haematology 20030401

• Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.

  Annals of hematology 20030401

• Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.

  Cell death and differentiation 20030401

• Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).

  Seminars in oncology 20030401

• Fludarabine in Waldenstrom's macroglobulinemia.

  Seminars in oncology 20030401

• Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030401

• Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment.

  Leukemia & lymphoma 20030401

• Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.

  Leukemia & lymphoma 20030401

• Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.

  Blood 20030315

• Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.

  Statistics in medicine 20030315

• Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.

  Cancer 20030315

• Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.

  Bioorganic & medicinal chemistry letters 20030310

• Increased CMV infection following nonmyeloablative allogeneic stem cell transplantation: a search for the guilty.

  Blood 20030301

• Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.

  American journal of hematology 20030301

• Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC).

  Haematologica 20030301

• Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20030301

• Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation.

  Bone marrow transplantation 20030301

• Purine nucleoside analogues in the treatment of myleoid leukemias.

  Leukemia & lymphoma 20030301

• Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia.

  Leukemia & lymphoma 20030301

• Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.

  Leukemia & lymphoma 20030301

• Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature.

  Leukemia & lymphoma 20030301

• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

  Blood 20030215

• Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.

  American journal of hematology 20030201

• Advances in the treatment of hairy-cell leukaemia.

  The Lancet. Oncology 20030201

• Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030201

• Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.

  British journal of haematology 20030201

• The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience.

  Transplantation proceedings 20030201

• A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

  Leukemia 20030201

• CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.

  Haematologica 20030201

• Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.

  Haematologica 20030201

• Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.

  Bone marrow transplantation 20030201

• Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

  Seminars in oncology 20030201

• Rituximab in chronic lymphocytic leukemia.

  Seminars in oncology 20030201

• Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine.

  Leukemia & lymphoma 20030201

• Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.

  Blood 20030115

• The effects of cladribine and fludarabine on DNA methylation in K562 cells.

  Biochemical pharmacology 20030115

• Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.

  Biochemical pharmacology 20030115

• Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

  Blood 20030101

• Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.

  Cancer gene therapy 20030101

• Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission.

  British journal of haematology 20030101

• Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia.

  Bone marrow transplantation 20030101

• Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.

  Acta haematologica 20030101

• Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20030101

• Phase I trial of fludarabine and paclitaxel in non-Hodgkin's lymphoma.

  Medical oncology (Northwood, London, England) 20030101

• The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.

  Archivum immunologiae et therapiae experimentalis 20030101

• [Long-term results of treatment of chronic B-cell lymphoid leukocytes in persons who participated in the elimination of the effects of the nuclear accident at the Chernobyl nuclear station].

  Likars'ka sprava 20030101

• Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma.

  Urologic oncology 20030101

• Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.

  The hematology journal : the official journal of the European Haematology Association 20030101

• Oral fludarabine.

  Drugs 20030101

• Oral fludarabine: a viewpoint by Dieter Huhn.

  Drugs 20030101

• Oral fludarabine: a viewpoint by David Oscier.

  Drugs 20030101

• Oral fludarabine: a viewpoint by Bruce D. Cheson.

  Drugs 20030101

• [Cytogenetic changes in the Namalwa cell line of human malignant lymphoma induced by inhibitors of DNA replication and synthesis].

  TSitologiia i genetika 20030101

• Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.

  Neoplasma 20030101

• Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.

  Blood 20021215

• Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.

  Blood 20021215

• Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

  Blood 20021215

• Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20021215

• Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.

  Blood 20021201

• Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.

  British journal of haematology 20021201

• Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.

  British journal of haematology 20021201

• Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

  Bone marrow transplantation 20021201

• Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.

  Bone marrow transplantation 20021201

• Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa.

  Bone marrow transplantation 20021201

• Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

  Clinical lymphoma 20021201

• Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.

  Haematologica 20021201

• Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.

  Journal of experimental & clinical cancer research : CR 20021201

• The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

  Blood 20021101

• Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

  Blood 20021101

• Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

  Blood 20021101

• Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.

  British journal of haematology 20021101

• Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine.

  Haematologica 20021101

• Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.

  Bone marrow transplantation 20021101

• [Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia].

  Revue neurologique 20021101

• [Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20021101

• [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].

  Deutsche medizinische Wochenschrift (1946) 20021025

• Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.

  Virology 20021025

• The triterpenoid CDDO induces apoptosis in refractory CLL B cells.

  Blood 20021015

• CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?

  American journal of hematology 20021001

• Non-myeloablative haematopoietic stem cell transplantation for severe aplastic anaemia with various complications.

  Clinical and laboratory haematology 20021001

• Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.

  British journal of haematology 20021001

• The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.

  Anti-cancer drugs 20021001

• Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

  Blood 20020915

• Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia.

  Blood 20020915

• Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915

• Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020915

• Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.

  Blood 20020901

• Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine.

  Molecular pharmacology 20020901

• Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.

  Leukemia 20020901

• Fludarabine treatment of cryoglobulinemic glomerulonephritis.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20020901

• Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.

  Haematologica 20020901

• Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.

  American journal of hematology 20020901

• Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.

  Chest 20020901

• Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.

  Bone marrow transplantation 20020901

• Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.

  Bone marrow transplantation 20020901

• Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.

  Annals of hematology 20020901

• Severe hypoglycemia in a patient with acute renal failure due to tumor lysis syndrome.

  The Israel Medical Association journal : IMAJ 20020901

• [Whipple's disease as a complication of chronic lymphocytic leukemia treated with fludarabine].

  Polskie Archiwum Medycyny Wewnetrznej 20020901

• Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia.

  Leukemia & lymphoma 20020901

• Increased apoptosis in B-chronic lymphocytic leukemia cells as a result of cyclin D3 down regulation.

  Leukemia & lymphoma 20020901

• Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.

  Seminars in oncology 20020801

• Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.

  Journal of hematotherapy & stem cell research 20020801

• Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.

  Bone marrow transplantation 20020801

• Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.

  European journal of haematology 20020801

• Waldenström's macroglobulinemia: a review of therapy.

  Leukemia & lymphoma 20020801

• Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.

  Leukemia & lymphoma 20020801

• Haploidentical stem cell transplantation for acute leukemia.

  International journal of hematology 20020801

• Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.

  International journal of hematology 20020801

• [Clinical pharmacology of nucleoside analogues].

  Bulletin du cancer 20020801

• Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.

  Oncogene 20020704

• Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.

  Blood 20020701

• Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.

  Haematologica 20020701

• Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine.

  Haematologica 20020701

• Continuous complete clinical and molecular remission in two patients with refractory lymphoid malignancies after autografting followed by allogeneic stem cell transplantation with reduced intensity conditioning.

  British journal of haematology 20020701

• Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.

  Cancer chemotherapy and pharmacology 20020701

• Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.

  American journal of hematology 20020701

• Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.

  American journal of hematology 20020701

• Cast nephropathy in a case of Waldenström's macroglobulinemia.

  Nephron 20020701

• Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia.

  European journal of haematology 20020701

• [Experience with fludarabine treatment and review of the literature].

  Orvosi hetilap 20020616

• Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.

  Haematologica 20020601

• Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.

  Leukemia 20020601

• Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.

  Leukemia 20020601

• Challenges in treating hematologic malignancies.

  Seminars in oncology 20020601

• Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.

  Clinical lymphoma 20020601

• Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.

  Clinical lymphoma 20020601

• Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

  Blood 20020515

• CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia.

  Leukemia research 20020501

• Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms.

  The American journal of surgical pathology 20020501

• Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues.

  American journal of hematology 20020501

• Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease.

  American journal of hematology 20020501

• Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.

  Cancer 20020501

• Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.

  Annals of hematology 20020501

• Fludarabine-induced eosinophilia: case report.

  Annals of hematology 20020501

• Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay.

  Japanese journal of cancer research : Gann 20020501

• A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20020501

• Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.

  The Netherlands journal of medicine 20020501

• Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.

  Cancer 20020401

• Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.

  Leukemia 20020401

• Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.

  Bone marrow transplantation 20020401

• Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.

  Pathology 20020401

• Immunochemotherapy in indolent non-Hodgkin's lymphoma.

  Seminars in oncology 20020401

• [Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].

  Der Internist 20020401

• [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].

  Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20020401

• Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.

  Leukemia & lymphoma 20020401

• Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.

  Blood 20020315

• Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

  Blood 20020315

• Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.

  Journal of leukocyte biology 20020301

• High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.

  British journal of haematology 20020301

• Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.

  Clinical lymphoma 20020301

• Correlation between chromosome damage and apoptosis induced by fludarabine and idarubicin in normal human lymphocytes.

  Toxicology 20020227

• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

  Blood 20020201

• Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.

  Haematologica 20020201

• Hematopoietic cell transplantation beyond first remission.

  Leukemia 20020201

• Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome.

  British journal of haematology 20020201

• Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

  Seminars in oncology 20020201

• Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.

  Seminars in oncology 20020201

• Emerging information on the use of rituximab in chronic lymphocytic leukemia.

  Seminars in oncology 20020201

• Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.

  Cancer 20020201

• Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.

  Leukemia & lymphoma 20020201

• Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine.

  Leukemia & lymphoma 20020201

• Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?

  European journal of haematology 20020201

• Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.

  European journal of haematology 20020201

• Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.

  Blood 20020115

• Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.

  Blood 20020101

• Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease.

  Experimental hematology 20020101

• Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.

  International journal of hematology 20020101

• Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020101

• Cellular and clinical pharmacology of fludarabine.

  Clinical pharmacokinetics 20020101

• Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer.

  Cancer treatment and research 20020101

• Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.

  Cancer treatment and research 20020101

• Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.

  Leukemia & lymphoma 20020101

• Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.

  European journal of haematology 20020101

• Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.

  Health technology assessment (Winchester, England) 20020101

• [Peripheral blood hematopoietic cell transplant using immunosuppressive chemotherapy without bone marrow destruction: 'minitransplant'].

  Gaceta medica de Mexico 20020101

• Current and developing chemotherapy for CLL.

  Medical oncology (Northwood, London, England) 20020101

• Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.

  Cytotherapy 20020101

• Waldenström's macroglobulinemia.

  Clinical journal of oncology nursing 20020101

• Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20020101

• The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.

  Cancer treatment and research 20020101

• Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.

  Medical oncology (Northwood, London, England) 20020101

• High molecular weight DNA fragmentation assay: a sensitive method for monitoring in vivo response to antileukemic chemotherapy.

  Anticancer research 20020101

• Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia.

  Annals of hematology 20020101

• Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia.

  Haematologia 20020101

• Analysis of recurrent failure times data: should the baseline hazard be stratified?

  Statistics in medicine 20011230

• Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.

  Blood 20011215

• Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings.

  Blood 20011215

• Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

  Blood 20011215

• Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.

  Blood 20011201

• Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study.

  British journal of haematology 20011201

• Nitric oxide enhancement of fludarabine cytotoxicity for B-CLL lymphocytes.

  Leukemia 20011201

• Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation.

  British journal of haematology 20011201

• Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.

  Blood 20011101

• Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.

  Blood 20011101

• Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease.

  Haematologica 20011101

• Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.

  Haematologica 20011101

• DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011101

• [Chronic lymphocytic leukemias].

  Nihon rinsho. Japanese journal of clinical medicine 20011101

• High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.

  Cancer 20011015

• Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.

  Cancer 20011015

• Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

  Leukemia 20011001

• Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.

  Haematologica 20011001

• Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.

  The Journal of rheumatology. Supplement 20011001

• Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine.

  Thrombosis and haemostasis 20011001

• A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.

  Bone marrow transplantation 20011001

• Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.

  Bone marrow transplantation 20011001

• Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.

  British journal of haematology 20011001

• Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.

  Annals of oncology : official journal of the European Society for Medical Oncology 20011001

• The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.

  Bone marrow transplantation 20011001

• Successful non-myeloablative stem cell transplantation for a heavily transfused woman with severe aplastic anemia complicated by heart failure.

  Bone marrow transplantation 20011001

• Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.

  Leukemia 20010901

• Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.

  Haematologica 20010901

• Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis.

  Journal of neuropathology and experimental neurology 20010901

• Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.

  British journal of haematology 20010901

• Therapeutic options for acute myelogenous leukemia.

  Cancer 20010901

• Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.

  Bone marrow transplantation 20010901

• Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.

  Annals of hematology 20010901

• Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.

  Annals of hematology 20010901

• Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010815

• Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

• Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.

  British journal of haematology 20010801

• Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.

  Bone marrow transplantation 20010801

• Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.

  Onkologie 20010801

• [Drug-induced hemolytic anemia].

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20010801

• Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?

  Transplantation 20010727

• Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells.

  Biochemical pharmacology 20010701

• Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

  Blood 20010701

• Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.

  Journal of clinical epidemiology 20010701

• Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.

  British journal of haematology 20010701

• Successful HLA-identical bone marrow transplantation in a patient with PNP deficiency using busulfan and fludarabine for conditioning.

  Bone marrow transplantation 20010701

• Acute left ventricular failure following melphalan and fludarabine conditioning.

  Bone marrow transplantation 20010701

• Unrelated cord blood transplantation in a Fanconi anemia patient using fludarabine-based conditioning.

  Bone marrow transplantation 20010701

• Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.

  Bone marrow transplantation 20010701

• Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.

  International journal of hematology 20010701

• Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.

  Leukemia & lymphoma 20010701

• [Chronic lymphocytic leukemia. 2. Therapy].

  Deutsche medizinische Wochenschrift (1946) 20010608

• [Chronic lymphatic leukemia. 3. The concrete case].

  Deutsche medizinische Wochenschrift (1946) 20010608

• UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.

  Experimental hematology 20010601

• Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

  Leukemia 20010601

• Paraneoplastic pemphigus: an association with fludarabine?

  The British journal of dermatology 20010601

• Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.

  Annals of the New York Academy of Sciences 20010601

• Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.

  Annals of hematology 20010601

• Non-myeloablative hematopoietic stem cell transplantation.

  Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20010601

• Combination chemotherapy and rituximab.

  Anti-cancer drugs 20010601

• Nucleoside analogues in the treatment of haematological malignancies.

  Expert opinion on pharmacotherapy 20010601

• Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.

  Expert opinion on pharmacotherapy 20010601

• Features of the engraftment of allogeneic hematopoietic stem cells using reduced-intensity conditioning regimens.

  Leukemia & lymphoma 20010601

• Novel treatment strategies in chronic lymphocytic leukemia.

  Current oncology reports 20010501

• Fatal legionella pneumonia after fludarabine treatment in chronic lymphocytic leukaemia.

  Journal of clinical pathology 20010501

• Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis.

  Pharmacotherapy 20010501

• A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.

  The British journal of dermatology 20010501

• Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine.

  Annals of oncology : official journal of the European Society for Medical Oncology 20010501

• [Molecular biology examination in chronic lymphocytic leukemia].

  Orvosi hetilap 20010422

• Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010415

• Fludarabine for chronic lymphocytic leukemia.

  The New England journal of medicine 20010412

• Fludarabine for chronic lymphocytic leukemia.

  The New England journal of medicine 20010412

• Fludarabine for chronic lymphocytic leukemia.

  The New England journal of medicine 20010412

• Fludarabine for chronic lymphocytic leukemia.

  The New England journal of medicine 20010412

• Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.

  Blood 20010401

• Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.

  American journal of hematology 20010401

• Fludarabine in the treatment of an active phase of a familial haemophagocytic lymphohistiocytosis.

  Archives of disease in childhood 20010401

• Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.

  Leukemia & lymphoma 20010401

• [Mantle cell lymphoma].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20010401

• Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine.

  Onkologie 20010401

• Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.

  Bone marrow transplantation 20010401

• Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010301

• Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.

  Haematologica 20010301

• Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.

  British journal of haematology 20010301

• New drug combinations for the treatment of murine AIDS and macrophage protection.

  European journal of clinical investigation 20010301

• Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.

  Experimental hematology 20010301

• Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

  Bone marrow transplantation 20010301

• Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.

  Bone marrow transplantation 20010301

• Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20010301

• Reversal of fludarabine induced testicular damage in a patient with chronic lymphocytic leukaemia (CLL), by suppression of pituitary-testicular axis using gonadotrophin releasing hormone (GnRH).

  Leukemia & lymphoma 20010301

• Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

  Blood 20010201

• Long-lasting complete remission of hepatitis C virus (HCV) infection and HCV-associated immunocytoma with alpha-interferon treatment.

  British journal of haematology 20010201

• Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation.

  British journal of haematology 20010201

• A case of refractory idiopathic pure red cell aplasia responsive to fludarabine treatment.

  British journal of haematology 20010201

• Bilateral breast relapse in acute myelogenous leukemia.

  Journal of pediatric hematology/oncology 20010201

• Reactivation of hepatitis B virus infection during cytotoxic chemotherapy.

  The American journal of gastroenterology 20010201

• Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010201

• Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.

  Leukemia & lymphoma 20010201

• Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma.

  Leukemia & lymphoma 20010201

• Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma.

  Leukemia research 20010101

• Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.

  Haematologica 20010101

• Red swollen nail folds and nail deformity as presenting findings in chronic lymphocytic leukaemia.

  British journal of haematology 20010101

• Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.

  Leukemia 20010101

• A fludarabine-based conditioning regimen for severe aplastic anemia.

  Bone marrow transplantation 20010101

• Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20010101

• Second allogeneic peripheral blood stem cell transplantation with fludarabine-based low-intensity conditioning regimen for relapsed myelodysplastic syndrome after allogeneic bone marrow transplantation.

  International journal of hematology 20010101

• Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.

  Acta haematologica 20010101

• Treatment of 'poor risk' acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.

  Leukemia & lymphoma 20010101

• First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.

  Leukemia & lymphoma 20010101

• Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.

  Leukemia & lymphoma 20010101

• Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia.

  Leukemia & lymphoma 20010101

• A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.

  Acta oncologica (Stockholm, Sweden) 20010101

• Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin's lymphoma.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20010101

• Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

  Leukemia & lymphoma 20010101

• Fulminant hepatic failure secondary to adenovirus following fludarabine-based chemotherapy for non-Hodgkin's lymphoma.

  Leukemia & lymphoma 20010101

• Angiogenic growth factors: autocrine and paracrine regulation of survival in hematologic malignancies.

  The oncologist 20010101

• Peripheral blood involvement in a mycosis fungoides patient with limited skin lesions: phenotypical features and homing molecule pattern.

  European journal of dermatology : EJD 20010101

• Chronic lymphocytic leukaemia.

  Clinical medicine (London, England) 20010101

• Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.

  Anticancer research 20010101

• [Lupus nephritis: treatments for today and tomorrow].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101

• [Nucleoside analogues--new drugs for the treatment of lymphatic cancers].

  Duodecim; laaketieteellinen aikakauskirja 20010101

• In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.

  Cytotherapy 20010101

• [Non-myeloablative therapy and allogeneic hematopoietic stem cell transplantation in hematologic malignancies].

  Polskie Archiwum Medycyny Wewnetrznej 20010101

• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  The New England journal of medicine 20001214

• Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenström macroglobulinemia.

  Leukemia & lymphoma 20000301

• Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

  Blood 19981115

• Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.

  Hematology and cell therapy 19980601

• Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.

  Anticancer research 19980101

• Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells.

  Leukemia 19941201

• Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.

  American journal of hematology 19941201

• Pentostatin increases the acute toxicity of high dose cyclophosphamide.

  Bone marrow transplantation 19930901

• Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia.

  Leukemia & lymphoma 19930301

• Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.

  Leukemia 19930301

• Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.

  Journal of medicinal chemistry 19920124

• In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.

  Molecular pharmacology 19820301